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Stress has profound effects on neuroendocrine function, 
increasing plasma corticosterone and prolactin levels, and plasma renin 
activity (PRA). Neurons in the hypothalamic paraventricular nucleus (PVN) 
play an important role as integrators of endocrine, autonomic and 
behavioral functions. The purpose of this dissertation research project 
was to investigate the role of neurons in, and afferents to, the PVN in 
mediating stress-induced neuroendocrine responses, specifically increased 
PRA, plasma renin concentration (PRC), and corticosterone levels. Male 
Sprague-Dawley rats were used for these experiments. The stressor 
consisted of a conditioned emotional (fear) response paradigm, which has 
been shown to cause increases in renin and corticosterone secretion. In 
this paradigm, each rat receives a footshock 10 minutes following 
placement in a chamber, and then was returned to his home cage. This 
procedure is repeated for three consecutive days. On the fourth day, 
instead of receiving shock 10 minutes after being placed in the test 
chamber, the rat is removed and sacrificed by decapitation. Trunk blood 
was collected for hormone assays. The experimental control rats were 
treated identically to rats in the treatment group with the exception that 
shock was not administered at any time. 
1 
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1. Effect of Electrolytic PVN Lesions on Stress-Induced Renin and 
Corticosterone Secretion. Bilateral electrolytic lesions in the PVN 
prevented the stress-induced increase in PRA, PRC and corticosterone 
levels. In contrast, electrolytic lesions in the thalamic nucleus 
reuniens, dorsal and caudal to the PVN, did not prevent the stress-induced 
increase in either PRA, PRC or corticosterone levels. Since the majority 
of the diencephalic corticotropin releasing factor (CRF) neurons are 
located in the parvocellular subnuclei of the PVN, it is not surprising 
that electrolytic PVN lesions prevented the stress-induced increase in 
corticosterone secretion. However, the finding that the stress-induced 
increases in PRA and PRC were also prevented was unexpected. 
2. Effect of Ibotenic Acid Lesions of Cells in the PVN on Stress-
Induced Renin and Corticosterone Secretion. Ibotenic acid is a selective 
neurotoxin that destroys cell bodies while leaving fibers of passage 
intact. To determine whether cell bodies in the PVN or fibers of passage 
mediate stress-induced increases in PRA, PRC and corticosterone levels, 
the cells in the PVN were selectively destroyed by injection of ibotenic 
acid. The corticosterone, PRA and PRC responses to stress were blocked 
by ibotenic acid injection. These observations suggest that neuronal cell 
bodies in the PVN mediate the stress-induced increase in PRA, PRC and 
corticosterone. 
3. Effect of 6-Hydroxydopamine-Induced Lesions in the PVN on 
Stress-Induced Renin and Corticosterone Secretion. Since the data 
indicated that cell bodies in the PVN mediate stress-induced renin and 
3 
corticosterone secretion, and the PVN is known to have an extensive 
catecholaminergic innervation, the next approach was to determine if 
catecholaminergic innervation of PVN neurons plays an important role in 
the neuroendocrine response to stress. This was accomplished by injection 
of the neurotoxin 6-hydroxydopamine (6-0HDA) into the PVN. 6-0HDA is 
taken up by the catecholaminergic nerve endings resulting in degeneration 
of these nerve terminals. Lesion placement and damage to noradrenergic 
nerve terminals was verified by immunocytochemical methods, using an 
antibody against dopamine E-hydroxylase. The 6-0HDA injections prevented 
the stress-induced increase in PRA, PRC and corticosterone levels, 
suggesting that intact catecholaminergic afferents to the PVN are critical 
for the stress-induced increase in renin and corticosterone secretion. 
4. Effect of Microinj ection of the E-Adrenoceptor Antagonist 
Sotalol into the PVN on Stress-Induced Renin and Corticosterone Secretion. 
The results from the experiment with 6-0HDA suggest that catecholaminergic 
nerve terminals in the PVN are involved in mediating the effect of stress 
on renin and corticosterone secretion. In previous studies, the H.-
adrenoceptor antagonist propranolol attenuated the stress- induced increase 
in PRA. Since propranolol is known to cross the blood-brain barrier, it 
is possible that &-receptors, located in the PVN, mediate the effect of 
stress on renin and corticosterone secretion. To test this hypothesis, 
the H.-adrenoceptor antagonist sotalol was microinj ected into the PVN. 
Sotalol prevented the stress-induced increase in corticosterone levels, 
but did not attenuate the stress-induced increase in PRA or PRC. The 
results suggest that a catecholaminergic input to cells in the PVN mediate 
4 
the effect of stress on renin and corticosterone secretion. Furthermore, 
stress-induced increases in corticosterone levels are mediated via &-
receptors, whereas stress-induced increases in PRA and PRC are mediated 





The renin-angiotensin system plays a role in the maintenance of 
sodium balance (Parfrey et al., 1981) and the regulation of blood pressure 
and volume (Fujii and Vatner, 1985). Renin is the enzyme responsible for 
the conversion of angiotensinogen to angiotensin I (AI), a decapeptide. 
AI is further converted to the octapeptide angiotensin II (All) by a 
peptidyl dipeptidase, converting enzyme. This reaction is slow in vitro, 
but rapid in vivo due to the activity of tissue-bound converting enzyme 
present on the luminal aspect of vascular endothelial cells throughout the 
body (Caldwell et al., 1976). Renin is the rate-limiting enzyme in the 
synthesis of All. All is the physiologically active component of the 
system and a potent pressor agent. All causes vasoconstriction by a 
direct action on vascular smooth muscle (Fujii and Vatner, 1985) and 
indirectly via the sympathetic nervous system (Peach et al., 1971). 
2. Description of Renin 
Renin is a glycoprotein with a molecular weight of about 40,000 
(Galen et al., 1979). Specifically, it is an aspartyl proteinase (Dzau 
and Pratt, 1986) that cleaves a leucine-leucine peptide bond between 
5 
6 
residues 10 and 11 of angiotensinogen. Renin has a circulation half-
life of 4-15 minutes (Michelakis and Mizukoshia, 1971; Gordon and Sull-
ivan, 1969; Gutman et al., 1973; Oates et al., 1974; Oparil et al., 1970; 
De Vito et al., 1977) and is metabolized by the liver and kidneys. 
Inactive forms of renin (prorenin and activation intermediates) have been 
found in the plasma of humans (Leckie, 1981), dogs (Wilczynski and Osmond, 
1983) and rats (Osmond et al., 1982). Prorenin is a circulating, high 
molecular weight form of renin with no intrinsic enzymatic activity 
(Sealey et al., 1979; lnagami and Murakami, 1980). Prorenin release 
following bilateral nephrectomy was reported to be under F..-receptor 
regulation (Wilczynski and Osmond, 1986). Nielsen and Poulsen (1988) 
reported that the kidney is the main source of inactive renin. 
3. Physiological Aspects of the Angiotensins 
a. Angiotensinogen (renin substrate) 
The glycoprotein angiotensinogen (approximate molecular weight 
60,000) is the substrate for renin. The main source of angiotensinogen 
is the liver. lmmunocytochemical studies (Richoux et al., 1983) and 
Northern Blot analysis with complementary mRNA sequences for angioten-
sinogen (lngelfinger et al., 1986) have shown that the liver contains and 
synthesizes angiotensinogen. Angiotensinogen is widely distributed in the 
blood and other extracellular fluids (Reid and Ramsay, 1975; Horky et al., 
1971; Keeton and Campbell, 1980). 
Plasma levels of angiotensinogen can be decreased by adrenalectomy 
(Carretero and Gross, 1967), hypophysectomy (Goodwin et al., 1970) and 
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diseases that impair liver function (Ayers, 1967). The administration of 
glucocorticoids, mineralocorticoids and sodium replacement can prevent the 
decrease in angiotensinogen levels produced by adrenalectomy (Nasjletti 
and Masson, 1969). Nephrectomy increases plasma levels of angiotensinogen 
(Hiwada et al., 1976; Carretero and Gross, 1967; Bing and Poulsen, 1969). 
This increase is thought to be mediated by adrenocortical steroids. 
Eggena and Barrett (1988) demonstrated an additive effect of nephrectomy 
and dexamethasone on the stimulation of renin substrate secretion. 
Freeman and Rostorfer (1972) observed that adrenalectomy caused a 70% 
reduction of the increase in plasma angiotensinogen caused by nephrectomy. 
Surgical stress, which stimulates the release of adrenocortical steroids, 
also increases plasma levels of angiotensinogen for several days in 
rabbits (Campbell et al., 1973; Romero et al., 1970; Morris et al., 1977). 
These studies suggest that an intact pituitary-adrenal axis is necessary 
for adequate substrate production. 
b. Angiotensin I (AI) 
The amino terminal decapeptide AI is cleaved from angiotensinogen 
by renin in the blood. Angiotensin I has been reported to act in a 
similar manner to All with respect to the adrenal medulla (stimulating 
the release of catecholamines) and the central nervous system (inducing 
thirst), but with lower potency (Fitzsimons, 1971; Peach, 1974). 
c. Angiotensin II (AII) 
All has many physiological effects, all of which are involved in 
the maintenance of blood pressure and plasma volume. All is a potent 
8 
pressor agent, acting directly on the vascular smooth muscle to cause 
vasoconstriction (Skeggs et al., 1956) and indirectly, via the sympathetic 
nervous system (Peach et al., 1971; Scroop et al., 1971). Similarly, All 
increases cardiac contractility in vitro by a direct action on the 
myocardium and indirectly via norepinephrine release from the cardioac-
celerator nerves (Blumberg et al., 1975). All acts on the peripheral 
arterioles to maintain arterial pressure in low cardiac output states 
(Davis and Freeman, 1976). 
All stimulates the secretion of aldosterone by a direct action on 
the zona glomerulosa of the adrenal cortex (Bartter et al., 1961; Biron 
et al., 1961). Blockade of All receptors decreases aldosterone production 
to nondetectable levels (Davis and Freeman, 1976). All also stimulates 
vasopressin secretion when administered intraventricularly in rats and 
dogs (Share, 1979; Keil et al., 1975) or intravenously in conscious dogs 
(Reid et al., 1982; Bonjour and Malvin, 1970), conscious rats (Knepel and 
Meyer, 1980) and humans (Uhlich et al., 1975; Padfield and Morton, 1977). 
Aldosterone and vasopressin act at the distal tubules of the kidney to 
increase sodium and water reabsorption, respectively. Together, they act 
to restore blood pressure and volume in response to the physiological 
stress of hypotension, hemorrhage and/or hypovolemia. 
All inhibits renin release when it binds to the juxtaglomerular 
(JG) cells (Dzau and Pratt, 1986), and increases the concentration of 
angiotensinogen in the plasma of dogs (Blair-West et al., 1974; Beaty et 
al., 1976) and rats (Nasjletti and Masson, 1973; Khayyall et al., 1973). 
All also stimulates secretion of angiotensinogen in vitro from rat 
hepatocytes (Klett and Hackenthal, 1987). It is likely that the 
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stimulation of angiotensinogen by All occurs via enhanced glucocorticoid 
secretion. All stimulates glucocorticoid secretion by a direct action on 
the adrenal cortex (Kaplan, 1965) and indirectly by potentiating the 
effect of CRF on ACTH secretion (Keller-Wood et al., 1986; Maran and 
Yates, 1977; Spinedi and Negro-Vilar, 1983). Reid et al. (1978) suggested 
that All stimulates angiotensinogen production to provide a positive 
feedback mechanism to prevent lack of substrate supply during periods of 
elevated renin secretion. 
4. Regulation of Renin Secretion 
a. Introduction 
Renin secretion from the kidney is regulated by a number of 
neural, chemical and mechanical factors. In general, factors that cause 
a decrease in either renal perfusion pressure, blood volume or plasma 
sodium concentration will stimulate renin secretion. 
Renin is secreted by the granular juxtaglomerular cells located in 
the afferent arterioles of the kidney (Taugner et al., 1979; Taugner et 
al., 1984). The juxtaglomerular cells are in close proximity to the 
macula densa, a specialized portion of the distal tubule that is sensitive 
to changes in sodium reabsorption across the tubular epithelium. The 
macula densa monitors the ionic environment in the tubular fluid and 
relays the message to either increase or decrease renin secretion. 
Studies by ltoh et al. (1985) suggest that adenosine, via the activation 
of A1 receptors, may be a signal from the macula densa to the juxta-
glomerular cells to inhibit renin release. It is reported that a decrease 
in the amount of sodium (Churchill et al., 1978), potassium (Shade et al., 
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1972) or chloride (Rostand et al., 1985) that crosses the macula densa 
cells will stimulate renin secretion. 
Renin secretion is also stimulated by a decrease in renal arterial 
pressure. The idea that a "pressor substance" (later to be known as 
renin) was secreted in response to a decrease in renal blood flow was 
first postulated by Goldblatt et al. (1934). This idea was further 
developed by Tobian et al. (1959) who suggested the existence of a renal 
baroreceptor that was responsible for the inverse relationship between 
blood pressure and renin secretion. 
Studies by Fahri et al. (1982) have shown that stimulation of renin 
secretion following a decrease in renal arterial pressure occurs via an 
intrarenal baroreceptor interacting with a renal B-receptor. Their 
studies have demonstrated that elevating plasma epinephrine concentration 
without changing blood pressure does not increase plasma renin activity. 
However, if epinephrine secretion accompanies a stimulus (e.g., hemor-
rhage) which also lowers blood pressure, then renin secretion will be 
increased. This system allows for plasma renin activity to be either 
stimulated or unaffected by high physiological levels of circulating 
epinephrine, depending on whether or not a hypotensive threat is involved. 
b. Role of the Sympathetic Nervous System in Renin Secretion 
The sympathetic innervation of the rat kidney consists of 
sympathetic cell bodies in paravertebral (thoracic T6 through lumbar L4) 
and prevertebral (renal, greater splanchnic, and celiac) ganglia 
(Sripairoj thikoon and Wyss, 1987). Stimulation of the renal nerves 
increases renin secretion (Di Bona, 1985; Blair et al., 1985). 
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stimulatory effect is mediated, at least in part, via norepinephrine 
released from the endings of the postganglionic sympathetic neurons that 
innervate the kidneys (Johnson et al., 1971; Taber et al., 1976). 
Circulating epinephrine can also stimulate renin secretion. The effect 
of stimulation of the renal nerves can be enhanced by activating beta (,8) 
receptors (Vander, 1965). Catecholamines are believed to stimulate renin 
secretion via a ,B-adrenergic mechanism since /3-antagonists have been shown 
to inhibit their effect both in vivo (Loeffler et al., 1972; Pettinger and 
Keeton, 1975) and in vitro (Weinberger et al., 1975; Vandongen et al., 
1973). The renin stimulating potency profile is isoproterenol > 
epinephrine > norepinephrine according to studies in conscious dogs by 
Johnson et al. (1979). Studies by Healy et al. (1985) and Osborn et al. 
(1981) suggest that the sympathetic nervous system stimulates renin 
release by activating B1 receptors on the juxtaglomerular cells. 
c. Role of Extra-Renal Beta Receptors in Renin Secretion 
Although there is evidence supporting intrarenal /3 receptor 
regulation of renin secretion, this does not exclude a role of extrarenal 
/3-adrenergic receptors that provide a powerful stimulatory effect on renin 
secretion. For example, Reid et al. (1972) observed increases in plasma 
renin activity and renin secretion following isoproterenol infusion into 
the femoral artery of dogs. Renal perfusion pressure was kept constant 
with an aortic clamp. However, infusion of the same doses of isoproter-
enol into the renal artery had no effect on plasma renin activity or renin 
secretion, suggesting that an extrarenal ,B receptor mechanism is involved 
12 
in regulating renin secretion. Johnson et al. (1979) obtained similar 
results with infusion of epinephrine and norepinephrine into the inferior 
vena cava (IVG) and renal artery. Epinephrine infusion into the IVG 
resulted in a 3. 5-fold increase in plasma renin activity while IVG 
infusion of norepinephrine resulted in a 1.5-fold increase in plasma renin 
activity. Infusion of epinephrine or norepinephrine directly into the 
renal artery to achieve similar arterial concentrations resulted in no 
increases in plasma renin activity. Fahri et al. (1982) suggested that 
the effect of epinephrine in the intact conscious dog can be explained as 
the combination of an extrarenal and intrarenal action. The extrarenal 
event is a generalized vasodilation that results in a drop in blood 
pressure which is sensed by the renal baroreceptor. The intrarenal action 
is mediated through intrarenal /3 receptors which affect the stimulus-
response curve of the renal baroreceptor. At the present time the 
location of the extrarenal /3 receptor has not been established. 
d. Role of Brain Serotonin (5-HT) Neurons in Renin Secretion 
In 1980, Zimmermann and Ganong demonstrated that injection of the 
5-HT precursors 5-hydroxytryptophan (5-HTP) or tryptophan to anesthetized 
dogs increased plasma renin activity. In humans, the 5-HT precursor L-
tryptophan was reported to increase renin secretion (Modlinger et al., 
1979), and the 5-HT antagonist cyproheptadine inhibited the secretion of 
renin induced by furosemide (Epstein and Hamilton, 1977). In rats, the 
5-HT releasers p-chloroamphetamine (PGA) and fenfluramine dose-dependently 
increased plasma renin activity via release of 5-HT from serotonergic 
nerve terminals (Van de Kar et al., 1981; 1985). The 5-HT2 antagonist 
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LY53857 dose-dependently inhibited the increase in plasma renin activity 
and plasma renin concentration following administration of fenfluramine 
and MK-212, a 5-HT agonist, suggesting that stimulation of 5-HT2 receptors 
enhances renin release (Lorens and Van de Kar, 1987). 
The effect of PCA on plasma renin activity was prevented by either 
pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine 
(PCPA) or by a chemical lesion of the dorsal raphe nucleus with the 5-HT 
neurotoxin, 5, 7-dihydroxytryptamine (Van de Kar et al., 1982). A 
mechanical lesion in the mediobasal hypothalamus, as well as postero-
lateral deafferentation of the hypothalamus (separating the hypothalamus 
from the midbrain) also blocked the effect of PCA on plasma renin activity 
(Karteszi et al., 1982). Anterolateral section through the retrochias-
matic area was ineffective in blocking the effect of PCA on plasma renin 
activity (Karteszi et al., 1982). These results suggest that a serotoner-
gic pathway, with cells in the dorsal raphe nucleus in the midbrain and 
terminals in the mediobasal hypothalamus, stimulates renin secretion. 
1. Role of Beta Receptors in the Serotonergic 
Stimulation of Renin Secretion 
There is evidence for f3 receptor involvement in mediating the 
serotonergic stimulation of renin secretion. Van de Kar and Richardson 
Morton (1986) demonstrated that the B1 and B2 antagonist sotalol and the 
B1 antagonist atenolol prevented the increase in plasma renin activity 
after the injection of PCA and fenfluramine. These findings supported 
those of Alper and Ganong (1984) who demonstrated that pretreatment with 
the sotalol and propranolol prevented the increase in plasma renin 
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activity produced by PCA. These studies suggested a possible role for 
the sympathetic nervous system in mediating the increase in renin 
secretion following the administration of 5-HT releasers. 
However, in rats which were adrenal medullectomized and sympathec-
tomized by chronic injections of 6-0HDA, there was no inhibition of the 
PCA- and fenfluramine-induced increase in plasma renin activity. Renal 
norepinephrine content was reduced to undetectable levels, suggesting that 
it is not likely that the serotonergic stimulation of renin secretion is 
mediated via the sympathetic nervous system or adrenal catecholamines (Van 
de Kar and Richardson Morton, 1986). These results seem to be in 
contradiction with the fact that the ~-adrenergic receptor antagonists 
sotalol and atenolol prevented the PCA- or fenfluramine-induced increase 
in plasma renin activity. However studies by Johnson (1984) and Johnson 
et al. (1979), as described earlier, provide evidence that~ receptors 
that mediate the increase in plasma renin activity are located outside the 
kidney, suggesting an entirely different mechanism of stimulating renin 
secretion. In addition, many beta receptor antagonists are known to bind 
to 5-HT receptors (Middlemiss et al., 1977) and it is possible that 
sotalol and atenolol are present in sufficient concentrations in the brain 
to block the 5-HT receptors and inhibit the serotonin-mediated increase 
in plasma renin activity (Lemmer et al., 1985; Garvey and Ram, 1975). To 
summarize, the data suggest that brain 5-HT neurons regulate renin 
secretion via a mechanism that is not related to the autonomic sympathetic 
nervous system or adrenal catecholamines. 
e. Role of the Hypothalamic Paraventricular Nucleus 
in Renin Secretion 
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The PVN plays a role in neurogenic and genetic models of hyperten-
sion (Ciriello et al., 1984; Zhang and Ciriello, 1985). The PVN is a 
logical central site to influence renin secretion as it receives afferent 
information from the baroreceptor region as well as having efferent 
projections to the sympathetic areas of the spinal cord (Sawchenko and 
Swanson, 1982). 
Electrolytic lesions in the PVN have been shown to prevent the 
increase in plasma renin activity produced by the 5-HT releasing drug PCA 
as well as preventing the increase in plasma renin activity that follows 
immobilization stress (Gotoh et al., 1987). Previous studies (Gotoh et 
al., 1985) demonstrated that bilateral knife cuts behind the hypothalamic 
paraventricular nucleus (PVN) reduced the renin response to immobilization 
and the gravitational stress of head-up tilting, suggesting a role for the 
PVN in both stress-induced and 5-HT- stimulated renin secretion. 
Electrical stimulation of the PVN in conscious rats increased 
plasma renin activity in a frequency-related manner. There were no 
significant changes reported in heart rate, mean arterial pressure or 
renal vascular resistance at any of the frequencies that produced an 
increase in plasma renin activity (Porter, 1986). These results suggest 
that neurons in the PVN stimulate renin secretion. 
Additional studies by Porter (1988) demonstrated the relationship 
between renal perfusion pressure and plasma renin activity during 
continuous low-level stimulation of the PVN. He found that for any given 
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decrease in renal perfusion pressure, the plasma renin activity increase 
was greater during the ongoing PVN stimulation. The effect of stimula-
tion of the PVN was prevented by both renal denervation and pretreatment 
with propranolol. These studies suggest that stimulation of the PVN 
elicits increased responsiveness of the kidneys to decreases in renal 
perfusion pressure, and that this effect is mediated via the sympathetic 
nervous system. 
f. Other Hypothalamic Areas Involved in Renin Secretion 
The lateral and posterior hypothalamic areas have long been known 
as sites where pressor responses can be elicited with electrical 
stimulation (Brody et al., 1986; Ciriello and Calaresu, 1977). Therefore 
it is not surprising that increases in plasma renin activity are also 
observed following electrical stimulation of the lateral (Zanchetti and 
Stella, 1975) and posterior (Natcheff et al., 1977) hypothalamus. Unlike 
the studies by Porter (1986) involving the PVN, these increases in plasma 
renin activity were accompanied by increases in blood pressure and 
required intact renal nerves. It is likely that the lateral and posterior 
hypothalamus exert their cardiovascular effects through long descending 
neuronal projections to the NTS (Kuypers et al., 1973) or ventrolateral 
medulla (Brody et al., 1986). 
Gotoh et al. (1987) reported that bilateral electrolytic lesions 
of the ventromedial nucleus prevented the increase in plasma renin 
activity produced by each of the following stimuli: the 5-HT-releaser PCA, 
immobilization, head-up tilt under inactin anesthesia, and a low-sodium 
diet. The authors hypothesize that the stimuli that increase plasma renin 
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activity via the ventromedial nucleus act by increasing sympathetic 
activity since the P-adrenergic receptor antagonist propranolol blocks the 
renin response to PCA, immobilization and head-up tilt. The PCA response 
is also abolished by another P-adrenergic receptor antagonist, sotalol, 
and by ganglionic blockade (Alper and Ganong, 1984). In addition, 
stimulation of the ventromedial nucleus increases blood pressure (Bunag 
and Inoue, 1985), while bilateral lesions of this nucleus prevent the 
development of experimental hypertension (Brody and Johnson, 1980). 
g. Extrahypothalamic Pathways Involved in Renin Secretion 
Other central nervous system sites play a role in renin release. 
Electrical stimulation of the ventrolateral medulla (Richardson et al., 
1974), dorsal medulla (Passo et al., 1971) and mesencephalic dorsal 
periaqueductal grey (Ueda et al., 1967) produced increases in plasma renin 
activity that were mediated via the renal nerves. 
h. Renin and Angiotensin in the Brain 
Administration of renin or All into the cerebral ventricles 
stimulates vasopressin secretion (Keil et al., 1975), increases drinking 
behavior and increases blood pressure (Reid and Ramsay, 1975). The 
anterior forebrain and nuclei of the anteroventral third cerebral 
ventricle (AV3V) play a role in the All-induced stimulation of drinking 
behavior, vasopressin release and increased arterial pressure. These 
brain areas are richly innervated by catecholaminergic fibers arising from 
cell bodies in the A2 area of the nucleus tractus solitarius, and other 
brainstem regions involved with central cardiovascular regulation (Saper 
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et al., 1983; Palkovits et al., 1974; Meldrum et al., 1984). Bellin et 
al. (1987) have shown that rats with 6-0HDA injections into the lateral 
cerebral ventricle had significantly attenuated drinking and blood 
pressure responses following both central and systemic All administration. 
Rats pretreated with desmethylimipramine (DMI) prior to injection of 6-
0HDA (to protect noradrenergic terminals) had no thirst or pressor 
response deficits following All administration. These results suggest a 
role for norepinephrine in mediating All-induced drinking and blood 
pressure responses. 
The distributions of angiotensin I and II, angiotensinogen, 
angiotensin-converting enzyme (ACE) and renin in the brain have been 
studied by various biochemical and irnrnunocytochemical techniques 
(Brownfield et al., 1982; Changaris et al., 1977; Fuxe et al., 1976; Fuxe 
et al., 1980; Basso et al., 1982; Fischer-Ferraro et al., 1971), although 
the physiological role for these substances is not clear. Ganong et al. 
(1979) suggested that All-like irnrnunoreactive material in the brain may 
be involved in modulating the release and action of brain catecholamines. 
The presence of a brain renin-angiotensin system is highly 
debatable. Fuxe et al. (1980) demonstrated renin-like irnrnunoreactivity 
in the paraventricular, periventricular and supraoptic nuclei in the rat 
and mouse. Dabsys et al. (1988) demonstrated an increase in angiotensin-
converting enzyme activity levels in the amygdaloid complex following 
bilateral destruction of the ventral noradrenergic pathway with 6-0HDA. 
There was a concomitant increase in arterial blood pressure that 
significantly correlated with the ACE activity levels in the amygdala. 
Studies in nephrectomized animals revealed All-like irnrnunoreactivity in 
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brain tissue (Phillips and Stenstrom, 1983) and significant elevations in 
angiotensinogen content in the hypothalamus and midbrain (Gregory et al., 
1982). However, the All-like material from rat brain has been shown to 
be different from authentic All by both gel filtration (Meyer et al., 
1982) and anion exchange HPLC techniques (Pohl et al., 1988). These 
studies indicated that the All-like material has a molecular weight of 
5000 7000 (compared to 1046 for All) and is more polar but less 
positively charged than All. 
Although indirect studies suggest the presence of each of the 
components of the renin-angiotensin system in the brain (Printz et al., 
1982) there is no evidence to support a functional brain renin-angiotensin 
system. Brownfield et al. (1982) have demonstrated that although 
angiotensin and converting enzyme immunoreactivities are present in the 
brain, they are not co-distributed, suggesting that there is no brain 
pathway for the formation of angiotensin. 
i. Role of Brain Catecholamines in Renin Secretion 
Norepinephrine in the brain was proposed to inhibit secretion of 
renin from the kidney through changes in sympathetic activity and 
secretion of vasopressin (Blair et al. , 1977; Reid et al. , 1978). The 
antihypertensive drug clonidine is an alpha (a) 2-agonist with a biphasic 
effect on blood pressure: a transient increase followed by a prolonged 
decrease. lntracerebroventricular injection of clonidine lowers plasma 
renin activity at a dose which is ineffective when given intravenously 
(Reid et al., 1975). Blair et al. (1977) have demonstrated that 
administration of L-DOPA to dogs pretreated with the peripheral decar-
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boxylase inhibitor carbidopa resulted in a drop in blood pressure and an 
inhibition of renin secretion. Since this treatment also increases brain 
catecholamine content, this study suggests that catecholamines formed from 
L-DOPA can act within the central nervous system to cause a decrease in 
renin secretion. In this study the decrease in plasma renin activity was 
dependent upon the presence of the renal nerves. 
The 5-HT releaser fenfluramine has a biphasic effect on plasma 
renin activity: an initial increase followed by a sustained decrease. 
Studies by Van de Kar et al. (1985) suggested that the initial increase 
in plasma renin activity following fenfluramine administration is mediated 
via release of serotonin, while the delayed, long-lasting suppression of 
plasma renin activity is mediated via a catecholaminergic mechanism. 
However, the long-term suppression of plasma renin activity following 
fenfluramine administration is not dependent on the peripheral sympathetic 
nervous system, as it was not prevented by adrenal enucleation combined 
with 6-0HDA-induced sympathectomy (Van de Kar et al., 1988). To 
determine whether a 2 -adrenoceptors mediate the suppressive effects of 
fenfluramine, the a 2-antagonists yohimbine and rauwolscine were injected 
prior to fenfluramine administration. Neither a 2-antagonist prevented the 
long-term suppressive effect of fenfluramine on plasma renin activity or 
plasma renin concentration. The data suggest that fenfluramine does not 
inhibit renin secretion by activating a 2-adrenoceptors in the CNS. This 
is in contrast to clonidine and a-methyl DOPA, which inhibit sympathetic 
outflow to the kidneys through activation of central a 2-adrenoceptors. 
Privitera et al. (1979) have shown that low doses of intracister-
nally-injected propranolol produced dose-dependent decreases in plasma 
21 
renin activity and mean arterial pressure (MAP), whereas identical doses 
given intravenously had no significant effect on plasma renin activity or 
MAP. A concomitant reduction in circulating norepinephrine levels was 
also seen. This study suggests that propranolol could be acting at a 
central ~-adrenergic site to suppress renin release. 
It is clear that central catecholamines play a role in mediating 
the suppression of plasma renin activity, but the site(s) of action and 
type of receptors involved have yet to be identified. 
B. CORTICOSTERONE 
1. Introduction 
In 1856 Brown-Sequard discovered that the adrenal glands are essential 
to life. By the 1930's it became clear that the adrenal cortex is the 
source of two vital classes of hormones: one, the glucocorticoids, 
regulate carbohydrate and protein metabolism, and the ability to tolerate 
prolonged stress (Selye, 1946; Selye, 1943; Cori and Cori, 1927; Britton 
and Silvette, 1931; Long et al., 1940). The second class is the 
mineralocorticoids, which control water and electolyte metabolism and the 
ability of the kidney to reabsorb sodium (Loeb et al., 1933; Harrop et 
al., 1933). Aldosterone is the primary salt-retaining hormone of the 
adrenal cortex and is synthesized in the glomerulosa layer of cortical 
cells. Cortisol (in humans) and corticosterone (in rats) are the main 
glucocorticoids secreted by the adrenal gland and are synthesized in the 
fasciculata layer. The fasiculata layer of cells in the adrenal cortex 
is stimulated by adrenocorticotropin hormone (ACTH) from the anterior lobe 
of the pituitary gland (Li et al., 1943; Sayers et al., 1943). Ingle et 
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al., (1938) found that ACTH secretion from the anterior pituitary is 
inhibited by secretions of the adrenal cortex. The role of the hypothal-
amus in integrating stimulatory and inhibitory inputs to the adenohypo-
physis was studied by Harris (1948) and Rasmussen (1938). Characteriza-
tion of the hypothalamic factor that stimulates corticotropin secretion 
(CRF) was completed by Vale et al. (1981). 
2. Corticotropin-Releasing Factor (CRF) 
CRF from ovine hypothalamic tissue is a 41-amino acid peptide that 
releases ACTH and ~-endorphin from anterior pituitary cells (Vale et al., 
1981; Plotsky, 1985; Rivier et al., 1983; Rivier and Vale, 1983). This 
peptide is 5-10 times more potent in releasing ACTH and ~-endorphin than 
vasopressin, which was originally thought to act as a corticotropin 
releasing factor (Saffran and Schally, 1977). Swanson et al. (1983) 
described the localization of CRF immunoreactive cells and fibers in three 
distinct systems in the rat brain. The first group is in the hypothalamic 
paraventricular nucleus (PVN). Approximately 2,000 CRF-stained cells are 
found in each of the eight subdivisions of the PVN, although most (80%) 
of the cells are concentrated in the parvocellular division (especially 
the periventricular and medial parts), and about 15% are found in the 
magnocellular division where oxytocinergic cells predominate. These CRF-
containing neurons are the only ones that demonstrated increased staining 
intensity following adrenalectomy. The second group of CRF-containing 
neurons are involved in mediating autonomic reponses. They include the 
central nucleus of the amygdala, bed nucleus of the stria terminalis, 
substantia innominata, lateral hypothalamic area, medial and lateral 
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preoptic areas, central periaqueductal grey, laterodorsal tegmental 
nucleus, locus coeruleus, dorsal vagal complex, parabrachial nucleus and 
regions containing the Al and AS catecholamine cell groups. The third 
group of CRF- immunoreactive cells are found in the cerebral cortex, 
especially layers II and III of the neocortex, and limbic regions such as 
the cingulate gyrus, prefrontal areas and areas bordering the rhinal 
fissure (Swanson et al., 1983). CRF-like immunoreactive neurons were also 
observed in the cerebellum and spinal cord (Olschowka et al., 1982). 
Outside the central nervous system, CRF-like immunoreactivity has been 
found in endocrine cells of the pancreas and gastrointestinal system, also 
in the liver, pituitary, adrenal, lung and placenta (Petrusz et al., 
1985). 
The parvocellular neurons of the PVN contain CRF (Merchenthaler et 
al., 1982; Liposits et al., 1983), which is transported along axons to the 
median eminence where it is released into the hypophyseal portal vessels. 
Makara et al. (1981) have shown that the CRF fibers in the stalk-median 
eminence region either originate from or run through the PVN. In the 
pituitary gland, CRF is then bound to specific membrane receptors of ACTH-
containing cells (Wynn et al., 1984; Leroux and Pelletier, 1984). ACTH 
release is stimulated which, in turn, increases steroid hormone production 
in the adrenal cortex. The glucocorticoids then exert negative feedback 
effects on both the hypothalamus (Yates and Urquhart, 1962) and anterior 
pituitary (Russell et al., 1969; Mulder and Smelik, 1977) via glucocor-
ticoid receptors (Gustafsson et al., 1983). ACTH immunoreactive fibers 
are found in most parts of the parvocellular division of the PVN and in 
the oxytocinergic cells of the magnocellular division (Sawchenko et al., 
24 
1982; Swanson and Sawchenko, 1983). 
Afferent connections to CRF neurons include presynaptic boutons 
containing immunoreactive ACTH 1-39 (Liposits et al., 1985) and CRF 
(Liposits et al., 1985), suggesting an autoregulatory process in the 
control of CRF release. Parvocellular CRF neurons also receive input from 
magnocellular neurons in the same nucleus (Leranth et al., 1983) and send 
processes to these magnocellular elements (Liposits et al., 1985). CRF 
neurons have been shown to have angiotensin II reactivity in adrenalec-
tomized, colchicine-treated rats (Lind et al., 1985). 
Rivier and Vale (1983) suggested that vasopressin may act 
synergisticallywith CRF under certain physiological conditions to promote 
ACTH secretion. In addition, in vitro studies have shown that vasopressin 
acts directly on the anterior pituitary corticotropes to stimulate ACTH 
secretion (Vale et al., 1983). Together, these results suggest that 
vasopressin may act synergistically with CRF under certain physiological 
conditions to promote ACTH secretion. 
Sawchenko (1987) demonstrated that adrenalectomy (ADX) enhanced 
both CRF and vasopressin immunoreactivity suggesting that they may be 
colocalized in parvocellular neurosecretory neurons of the PVN. Other 
studies support this observation (Tramu et al., 1983; Kiss et al., 1984; 
Sawchenko et al., 1984; Piekut and Joseph, 1985). Dual immunocytochemical 
studies have shown the co-localization of CRF and vasopressin in the 
parvocellular neuronal perikarya in the PVN. In general, CRF immunos-
tained cells are concentrated in the medial parvocellular part of the PVN, 
while the vasopressin neurons are predominantly in the magnocellular part 
of the PVN. However, in adrenalectomized, colchicine-treated rats, a 
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dense accumulation of vasopressin-imrnunoreactive cells were seen in the 
medial parvocellular part of the PVN, in a similar distribution to that 
seen for CRF- containing cell bodies (Piekut and Joseph, 1986). Extra-
hypothalamic sites of ADX-enhanced CRF imrnunoreactivity included the 
cerebral cortex, arnygdala and the bed nucleus of the stria terminalis. 
These extra-hypothalamic sites contained no vasopressin imrnunoreactivity 
colocalized with the CRF (Sawchenko, 1987). Hypophysectomy as well as ADX 
has been shown to enhance CRF imrnunostaining in PVN cell bodies (Bugnon 
et al., 1983; Merchenthaler et al., 1983; Paull and Gibbs, 1983; Swanson 
et al., 1983). Sawchenko (1987) reported that hypophysectomy produced 
results comparable to ADX-enhanced CRF and vasopressin staining in the 
PVN. Low doses of dexamethasone attenuated and high doses prevented the 
ADX-induced enhancement of CRF and vasopressin imrnunoreactivity, with the 
adrenal steroid potency profile as dexamethasone > corticosterone > 
deoxycorticosterone > aldosterone. These results suggest that adrenal 
steroids, particularly glucocorticoids, play a primary role as regulators 
of peptide expression. 
3. Other Factors Affecting ACTH Release 
Other neuropeptides that stimulate the release of ACTH include 
angiotensin II (All) (Ramsay et al., 1978; Steele et al., 1981) and 
oxytocin (Beny and Baertschi, 1980; Pearlmutter et al., 1974). In vitro 
dose-response studies by Spinedi and Negro-Vilar (1983) ranked the 
corticotropin-releasing activity as follows: CRF > vasopressin > oxytocin 
> AII. The stimulatory effects of AII may involve the stimulation of AII 
receptors in the anterior pituitary (Hauger et al., 1982; Mukherjee et 
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al., 1982) or the hypothalamic PVN (Saavedra et al., 1986). The density 
of the All binding sites in the PVN have been shown to increase following 
repeated immobilization stress (Castren and Saavedra, 1988). It is 
possible that All receptors in the PVN play a role in modulating stress-
induced corticosterone secretion. 
4. Role of Brain Catecholamines in Corticosterone Secretion 
a. Introduction 
In general, the ascending noradrenergic pathways appear to relay 
afferent visceral information to the forebrain (Cunningham and Sawchenko, 
1988). There has been considerable controversy as to whether catechol-
amines play an excitatory or inhibitory role in corticosterone secretion. 
Norepinephrine and/or epinephrine have been implicated as stimulators of 
the secretion of virtually every anterior pituitary hormone (Sawchenko and 
Swanson, 1982). With respect to ACTH secretion, brain catecholamines were 
originally postulated to have an inhibitory role (van Loon et al., 1971; 
Weiner and Ganong, 1978; Cuello et al., 1973; Scapagnini et al., 1970). 
However, in recent years more accurate and reliable anatomical and 
pharmacological studies suggest a stimulatory role for catecholamines in 
corticosterone secretion (Szafarczyk et al., 1985; Feldman et al., 1988; 
Alonso et al., 1986; Guillaume et al., 1987). 
b. Anatomical Evidence 
The predominantly noradrenergic (Sawchenko and Swanson, 1981) 
nucleus of the solitary tract (NTS) sends fiber projections to the 
parvocellular PVN, substantia innominata, central nucleus of the amygdala 
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and bed nucleus of the stria terminalis (Ricardo and Koh, 1978), all of 
which contain CRF-stained cells (Swanson et al., 1983). Swanson et al. 
(1983) suggested that the nucleus of the solitary tract, which receives 
direct vagal and glossopharyngeal afferents (Beckstead and Norgren, 1979) 
could serve as a major relay point of visceral sensory information to CRF 
cell bodies in the basal forebrain. Likewise the parabrachial nucleus, 
which receives a large input from the NTS (Norgren, 1978), and the locus 
coeruleus also project to many of the sites that contain CRF-immunoreac-
tive cell bodies, including the parvocellular PVN, the bed nucleus of the 
stria terminalis and the central nucleus of the amygdala. These nuclei 
may also be involved in the relay of visceral sensory information to CRF 
cell bodies (Swanson et al., 1983). 
Another fiber projection is described from the predominantly 
noradrenergic cells in the Al region of the ventrolateral medulla (which 
receives an input from the NTS) to the magnocellular (vasopressinergic) 
and parvocellular PVN. Reciprocal connections have also been described 
from the parvocellular PVN to the dorsal vagal complex and spinal cord 
(Hosoya and Matsushita, 1979; Swanson and Kuypers, 1980). Electrophysio-
logical studies by Kannan and Yamashita (1985) have also demonstrated 
reciprocal connections between neurons in the NTS region and the PVN. 
Studies by Skofitsch et al. (1985) have demonstrated binding sites for CRF 
in sensory areas of the rat hindbrain and spinal cord, specifically in the 
posterior part of the NTS, the substantia gelatinosa nervi trigemini and 
laminae I and II of the spinal cord. Since these areas are rich in nerve 
endings of primary sensory neurons, this observation suggests a possible 
role for CRF in mediating peripheral sensory processes. 
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Cunningham and Sawchenko (1988) used an immunofluorescence double-
labeling procedure to determine which anterogradely labeled fibers and 
terminals in the PVN also displayed dopamine P-hydroxylase immunoreac-
tivity, indicating the presence of catecholaminergic neurons. Specifical-
ly, projections from the Al (caudal ventrolateral medulla) region were 
found to synapse on magnocellular vasopressinergic neurons in the PVN, 
while projections from the A2 (medial part of the NTS) region were located 
primarily throughout the parvicellular division of the PVN. The 
projections were the most dense in the dorsal medial parvicellular region, 
which is known to contain a large population of CRF- immunoreactive 
neurons. A less-dense projection was found in the magnocellular division 
of the PVN. The A6 (locus coeruleus) projections were found almost 
exclusively in the parvicellular division of the PVN, specifically in the 
periventricular zone, which contains dopamine, somatostatin and thyrotrop-
in-releasing hormone-containing neurons. These findings provide 
anatomical evidence that the noradrenergic cells in the medial NTS 
innervate CRF-immunoreactive cells in the PVN. 
Liposits et al. (1986) showed that PNMT-immunoreactive axon 
terminals have synaptic connections with dendrites, somata and spinous 
structures of CRF-immunoreactive neurons. The parvocellular subnuclei 
demonstrated a more intense adrenergic innervation than the magnocellular 
subnuclei. The mammalian anterior pituitary does not receive catechol-
aminergic innervation, unlike the neural and intermediate lobes which 
receive noradrenergic and dopaminergic innervation (Bjorklund et al., 
1967; Saavedra et al., 1975). 
c. Role of the Ventral Noradrenergic Bundle in 
Corticosterone Secretion 
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The ventral noradrenergic bundle (VNAB) originates from the 
medullary Al and A2 cell groups, and the pontine locus coeruleus. It 
extensively innervates the hypothalamus, conveying most of the catechol-
aminergic innervation to the PVN (Moore and Bloom, 1979; Palkovits, 1981; 
Swanson and Sawchenko, 1980). The VNAB is thought to be the source for 
the noradrenergic modulation of ACTH secretion (Szafarczyk et al., 1985; 
Feldman et al., 1988). Also, afferents from the epinephrine-containing 
cell groups (Cl-C3) reach the hypothalamus via the VNAB (Ungerstedt, 
1971). 
Injections of 6-0HDA into the VNAB significantly reduced CRF levels 
in hypophysial portal blood (HPB) as well as producing significant 
depletion of hypothalamic norepinephrine and epinephrine (Guillaume et 
al., 1987). Similar results were obtained by Eckland et al. (1988), who 
found that 6-0HDA injections into the VNAB or the lateral ventricles 
caused a reduction of HPB CRF concentration. However, HPB norepinephrine 
was reduced only with the i.c.v. 6-0HDA injections and was unchanged in 
the VNAB-lesioned group. 
Further support for a stimulatory role of norepinephrine in CRF 
secretion is provided by Plotsky (1987). The increase in hypophysial-
portal immunoreactive CRF (irCRF) following electrical stimulation of the 
VNAB was prevented by i.c.v. pretreatment with the a 1-adrenoceptor 
antagonist corynanthine, but not by the ~-adrenergic antagonist propran-
olol. Corynanthine also blocked the dose-dependent increases in irCRF 
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following icv administration of norepinephrine (0.1-5.0 nmol). In 
contrast, 5 nmol or greater doses of norepinephrine resulted in a dose-
dependent inhibition of irCRF release that could be blocked by propran-
olol, but was unaffected by corynanthine. This suggests that low doses 
of norepinephrine stimulate CRF release via an a-receptor mechanism, 
whereas higher doses of norepinephrine inhibit CRF release via a &-
receptor. 
d. Stimulation of CRF/Corticosterone Secretion by Epinephrine 
and Norepinephrine 
Microinjections of norepinephrine (40 nmoles) into the PVN 
significantly increased serum corticosterone levels. Epinephrine (40 
nrnoles) microinjections into the PVN were even more efficacious than 
norepinephrine in increasing serum corticosterone levels, whereas dopamine 
(40 nrnoles) had no effect (Leibowitz et al., 1986). 
Intravenous infusion of either !-epinephrine or the P-adrenoceptor 
agonist 1-isoproterenol into pentobarbital anesthetized rats resulted in 
a dose-dependent increase in plasma corticosterone levels. The effect of 
epinephrine and isoproterenol on plasma corticosterone levels was 
associated with a parallel and dose-related increase in plasma ACTH 
(Berkenbosch et al., 1983). 
Tilders et al. (1985) found that intravenous infusion of epineph-
rine increased plasma ACTH and corticosterone to levels that are 
comparable to those induced by stress. The stimulation of ACTH secretion 
by epinephrine appears to be mediated via CRF and P-adrenergic receptors 
since it was prevented by i.p. injections of propranolol or administration 
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of CRF antiserum. 
In vitro studies with incubated rat hypothalami demonstrated that 
norepinephrine produced a dose-dependent stimulation of CRF release which 
was prevented by the ~-adrenoceptor antagonists propranolol and timolol. 
The norepinephrine-induced CRF release was not affected by the a 1-
adrenoceptor antagonists thymoxamine, prazosin or corynanthine or the a2-
adrenoceptor antagonist idazoxan (Tsagarakis et al., 1988). This study 
suggests a stimulatory role for norepinephrine on CRF release that is 
mediated by~ receptors. 
e. Role of Dopamine Neurons in Corticosterone Secretion 
The PVN is uniformly innervated with dopaminergic neurons. The 
dopaminergic innervation of the PVN originates from cells of the arcuate 
nucleus (Al2), zona incerta (A13) and periventricular nucleus (Al4) 
(Hokfelt et al., 1984). Immunocytochemical studies indicated that both 
dopamine and norepinephrine terminals synapatically contact magnocellular 
neurons on their dendrites or cell bodies (Decavel et al., 1987). In 
addition, tyrosine hydroxylase immunoreactivity has been reported in both 
fibers and neurons of the PVN (Swanson et al., 1981; Liposits et al., 
1986). 
Dopamine has been shown to stimulate corticosterone secretion. 
Injection (i.p.) of the dopamine agonist pergolide caused a dose-dependent 
increase in plasma corticosterone levels, which was blocked by pretreament 
with the dopamine antagonists spiperone and haloperidol. Spiperone also 
partially inhibited the increase in plasma corticosterone levels following 
administration of quipazine, a serotonin agonist, although much higher 
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doses were required than for pergolide. In addition, the peripheral 
dopamine antagonist domperidone did not prevent the increase in plasma 
corticosterone levels by pergolide (Fuller and Snoddy, 1981). These 
results support a role for central dopamine receptors in corticosterone 
secretion. Similar results were obtained by Jezova et al (1985), who 
found that subcutaneous injection of the dopamine agonist apomorphine 
increased plasma ACTH and corticosterone levels. Haloperidol pretreatment 
completely inhibited the apomorphine-induced stimulation in plasma ACTH. 
5. Role of 5-HT Neurons in Corticosterone Secretion 
Many studies support the hypothesis that stimulation of serotonergic 
receptors leads to increased corticosterone secretion in unstressed 
animals (Buckingham and Hodges, 1979; Fuller and Snoddy, 1980; Fuller, 
1981; Jones et al., 1976; Van de Kar et al., 1982). Gibbs and Vale (1983) 
reported that administration of the 5-HT uptake inhibitor fluoxetine to 
anesthetized rats caused increased release of CRF-41 into hypophyseal 
portal blood. Lorens and Van de Kar (1987) demonstrated that plasma 
corticosterone levels were increased by the 5-HT agonist MK-212, the 5-
HT1A agonists ipsapirone and 8-hydroxy-2-(di-N-propylamino)tetralin (8-0H-
DPAT) , and the serotonin releaser fenfluramine. The 5-HT2 antagonist 
LY53857 did not prevent the effect of MK-212 and fenfluramine on 
corticosterone secretion. These data suggest a possible role for 5-HT1A 
receptors in the stimulation of corticosterone secretion. This conclusion 
was confirmed by Koenig et al. (1987) and Gilbert et al. (1988). 
The dorsal and median raphe nuclei in the midbrain are known to be 
the major sources of serotonergic pathways to the hypothalamus (Azmitia 
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and Segal, 1978; Parent et al., 1981; Van de Kar et al., 1980). In 
particular, the median raphe nuclei are the primary source of 5-HT fibers 
to the suprachiasmatic nucleus, anterior hypothalamic area and medial 
preoptic area, while the anterolateral hypothalamic area and arcuate 
nucleus receive 5-HT inputs from both the dorsal and median raphe nuclei 
(Van de Kar and Lorens, 1979). 
With respect to the PVN, a relatively light serotonergic innerva-
tion has been described (Aghajanian et al., 1973; Steinbusch, 1981). 
Immunocytochemical studies by Sawchenko et al. (1983) found that the major 
source of ascending serotonergic projections to the PVN were from the 
dorsal and median raphe nuclei and the medial lemniscus. A significant 
decrease in PVN serotonin was reported following surgical destruction of 
the dorsal raphe nucleus (Palkovits et al., 1977). 
Immunocytochemical studies by Liposits (1987) demonstrated a 
moderate serotonergic innervation to the PVN, with a prominent distribu-
tion to the parvocellular subnuclei. Serotonergic axons were found to 
overlap with CRF-immunoreactive axons. Further ultrastructural examina-
tion revealed that serotonin-containing terminals formed axo-dendritic and 
axo-somatic synapses with CRF-immunoreactive neurons. This study suggests 
that serotonin can influence CRF-containing neurons via synaptic 
transmission. 
Midline injections of 5,7-dihydroxytryptamine (5,7-DHT) into the 
raphe nuclei produced significant depletions of 5-HT in the hypothalamus, 
and prevented the increase in corticosterone following stimulation of 
cortical and limbic areas (dorsal hippocampus, basolateral amygdala, 
mesencephalic reticular formation and medial septal nucleus). The ether-
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induced increase in corticosterone levels was not affected by this lesion. 
Injection of 5, 7-DHT into the PVN also prevented the adrenocortical 
response to dorsal hippocampal and photic stimulation. These results 
suggest that 5-HT in the PVN mediates the stimulation of corticosterone 
secretion following either peripheral or central stimuli (Feldman et al., 
1987). 
In contrast, Van de Kar et al. (1982) demonstrated that the PCA-
induced stimulation of corticosterone secretion was not mediated by either 
the dorsal or median raphe nucleus. In addition, posterolateral cuts 
which interrupted caudal inputs to the hypothalamus did not block the 
serotonergic stimulation of corticosterone secretion by the serotonin-
releasing drug PCA (Van de Kar et al., 1985). 
Serotonin has been shown to play a role in mediating the diurnal 
variation in basal plasma corticosterone in rats. Plasma corticosterone 
levels peak at the onset of the dark cycle in the rat (Krieger and Hauser, 
1978; Wilkinson et al., 1979). Depletion of brain serotonin with p-
chlorophenylalanine (PCPA) raised the morning low and prevented the 
evening increase in plasma corticosterone (Scapagnini et al., 1971; 
Vernikos-Danellis et al., 1973). Similar results were observed with rats 
fed a tryptophan-free diet for 21 days (Vernikos-Danellis et al., 1977). 
In humans, plasma cortisol and ACTH levels also follow a diurnal rhythm, 
except that the highest levels are found in the morning (0600h), with the 
lowest values at night (2200h) (Watabe et al., 1987). This study 
demonstrated a similar diurnal pattern for plasma CRF, with peak values 
at 0600h and significantly lower levels at 1800h and 2200h. These results 
suggest that the diurnal rhythm in CRF secretion plays a role in 
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regulating the diurnal rhythm in cortisol and ACTH secretion. 
In conclusion, the studies presented in this section demonstrate the 
presence of CRF cell bodies in the PVN, and a role for brain catechol-




Stress has been defined by Hans Selye (1973) as the "non-specific 
response of the organism to any demand made upon it" (Selye, 1973). By 
this definition, the word "stress" describes a response, but it is often 
used interchangeably with the stimulus or "stressor" that elicits the 
response (Mills, 1985). The stress response can occur following a wide 
variety of stimuli. Stressors can be classified as physiological, 
environmental or psychological. Physiological stressors include surgery, 
injection of foreign substances such as proteins, diseases, anesthesia, 
loss of blood, exercise and trauma. Environmental stressors include 
prolonged exposure to cold or heat, noise, radiation, pollutants and 
chemicals. Psychological stressors include a threatening predator, 
intense competition among members of the same species, prolonged conflict, 
learning how to avoid a painful stimulus (such as electric shock), 
conditions characterized by novelty, anticipation, fear, unpredictability 
and change (Kidman, 1984; Gray, 1971; Mills, 1985). 
b. Cannon's Alarm Reaction 
Cannon (1914) described the role of the sympathetic nervous system 
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in the "fight or flight" emergency or "alarm reaction". This reaction 
permits the body to perform more strenuous muscle activity than normally 
possible. Cannon noted that when animals underwent stressful situations 
there was a marked increase in the activity of sympathetic nerves. This 
stimulation of the autonomic nervous system mobilizes the body's resources 
to deal with the stressful situation. The alarm reaction is thought to 
be transmitted from the hypothalamus through the reticular formation to 
the spinal cord to evoke massive catecholamine release from the sym-
pathetic nerve endings (Guyton, 1981). 
c. Selye's General Adaptation Syndrome 
Selye (1936) was the first to describe a biological stress syndrome 
produced by diverse noxious agents. His description subsequently became 
known as the "general adaptation syndrome", a three-stage process that 
describes the long-term adjustments elicited by prolonged stress. The 
first stage is the "alarm reaction", when the body is exposed to diverse 
stimuli to which it has not adapted. Following the initial alarm 
reaction, a "stage of resistance" occurs in which resistance to the 
original stressor (which continues to exist) is increased, but resistance 
to other stressors is decreased. If the stressor continues for a long 
enough time, the stage of resistance develops into a final "stage of 
exhaustion", with a catastrophic decline in resistance to all other types 
of stressors. If the stress reaction continues undiminished, death ensues 
(Selye, 1976). 
In cases of prolonged stress, Selye (1946) described a major role 
for glucocorticoids during the alarm reaction. Glucocorticoids increase 
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sugar deposition in the liver and facilitate the conversion of proteins 
and fats into sugars. They enhance the responsiveness of the blood 
vessels to epinephrine and norepinephrine. This will provide the body 
with energy sources to be rapidly utilized in the event of sudden 
strenuous activity. Glucocorticoids also lower the body's resistance to 
infection and have anti-inflammatory properties, including decreased 
numbers of lymphocytes and eosinophils, decreased thymus weight and 
inhibition of antibody formation. Stress appears to play a major role as 
a suppressor of immune function. 
Other physiological changes induced by prolonged stress include a 
depression of thyroid activity, inhibition of body growth, and suppression 
of sexual and reproductive behavior (Gray, 1971). In simple terms, the 
body copes with prolonged stress by closing down any process that detracts 
from immediate energy mobilization. 
d. Sympathetic and Endocrine Stress Responses 
The biological stress response is believed to be mediated by the 
stimulation of two systems (Kidman, 1984). One, the pituitary-adrenal 
axis, is activated by sensory nerves which relay information regarding 
external stressors to the hypothalamus. Hypothalamic neurons contain CRF 
and release it into the portal circulation, stimulating the anterior 
pituitary gland to produce and release ACTH. In response, the adrenal 
cortex produces corticosteroids. The glucocorticoids liberated into the 
bloodstream inhibit the synthesis and/or release of ACTH from the 
pituitary by a negative feedback mechanism. 
The second system is the sympathetic adrenal medullary axis, which 
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plays an important role in the alarm reaction described by Cannon. In 
this system, once the sensory nerves relay the information regarding the 
external stressors to the hypothalamus, it relays a message through the 
reticular formation to the spinal cord to evoke massive catecholamine 
release from the sympathetic nerve endings and adrenal medulla. 
e. Physiological Changes in Response to Stress 
Selye (1950) emphasized the fact that the physiological changes 
(primarily in the adrenal cortex) in response to stressful stimuli were 
the same irrespective of the stimulus used. This suggests that whether 
the stressor is physiological, environmental or psychological, the 
biological stress response would always be the same. This general 
hypothesis allows for comparison of physiological responses following a 
variety of different stressors. 
Since stress is abstractly defined, it is helpful to have 
quantifiable parameters that are known to change when animals or humans 
are exposed to a stressor. In the experiments presented in this 
dissertation, the neuroendocrine responses to stress were measured with 
respect to plasma renin activity and plasma corticosterone levels. The 
stressor was a behavioral paradigm known as conditioned fear, or 
conditioned emotional response (CER), designed to produce psychological 
stress. 
B. The Conditioned Fear Paradigm 
a. Description 
Each rat was transported from his home cage to the stress chamber. 
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Ten minutes following placement in the chamber, the experimental 
(stressed) rat received an inescapable foot shock and was returned to his 
home cage. This procedure was repeated for three consecutive days. In 
previous experiments it was apparent that the stressed rats had learned 
that their placement in the chamber will be followed by a foot shock. By 
the third day, in contrast to the control animals, the stressed rats 
defecated, urinated and demonstrated freezing (no movement) behavior. On 
the fourth day, after 10 minutes in the test chamber, instead of receiving 
shock the rat was removed, transported to a third area outside the stress 
room and immediately sacrificed by decapitation. The control rats were 
treated identically except that shock was not administered at any time. 
A more detailed description of this procedure can be found in the Methods 
section. 
b. Pavlov's Dog: Classical Conditioning 
Ivan Pavlov (1927) presented studies on classical conditioning in 
which a dog was repeatedly exposed to a situation where an initially 
neutral stimulus (e.g., a tone or light flash) was followed directly by 
a stimulus of biological significance to the animal (food). The latter 
"unconditioned stimulus" (UCS) elicited a range of "unconditioned 
responses" (UCR) . As the pairings of stimuli were continued, the 
originally neutral stimulus became a "conditioned stimulus" (CS), capable 
of eliciting some part of the responses formerly elicited exclusively by 
the UCS. This "conditioned response" (CR) in Pavlov's dogs was saliva-
tion. 
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c. Definition of Fear 
Fear can be defined as an emotional response to an aversive 
stimulus. In this respect, it is classified as an emotion. The common 
element that emotions share is that they represent a reaction to a 
"reinforcing event" or signals of reinforcing events. Reinforcing events 
include both rewards and punishments. An example of a punishment would 
be the removal of a reward, or the failure of an expected reward to occur. 
The emotional responses will depend on the type of reinforcing event and 
the animal's knowledge of these events (Gray, 1971). 
d. Measures of Fear 
Hall (1941) established the link between the study of fearfulness 
and the use of defecation as a measure of fear. He developed a standard 
test (the Open Field) for the measurement of emotional defecation. Parker 
(1939) demonstrated that defecation occured in response to a variety of 
situations which one would expect to elicit fear. He recorded the amount 
of defecation elicited by six different situations: the Open Field test, 
a buzzer, sudden dropping, a tilting box that caused the rat to slide down 
an inclined plane, immobilization and forced swimming. High positive 
correlations were obtained between the scores on every test. Further 
factor analysis indicated a general factor (presumably fear) which all the 
tests were measuring. These results support the statement by Selye (1950) 
that physiological changes in response to stressful stimuli are the same 
irrespective of the alarming stimulus used. 
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e. Emotional Factors 
There are physiological events that occur within an animal to 
influence its behavior in a given environment. In 1890, William James 
and Carl Lange independently expressed a theory for the interrelationship 
between physiological events and emotional responses. The James-Lange 
theory, as it is known, defines emotions as the perception of the 
physiological changes that occurred in response to a stimulus. For 
example, the feeling of being frightened would consist solely of feeling 
your heart pound, your breathing become faster, and so on. Unfortunately, 
it is not possible to isolate specific physiological functions and 
correlate them exclusively with a particular emotional state. However, 
the role of emotional factors should not be overlooked. Studies by Mason 
et al. (1976) recognize the sensitivity of the pituitary-adrenal cortical 
system to psychological influences. Departing from Selye's non-specific 
physiological response hypothesis (1950), Mason et al. (1976) proposed 
that there are similar psychological reactions to various external 
stimuli. Factors such as heat, cold, fasting or exercise do not produce 
an adrenal cortical response if emotional arousal is carefully avoided 
(Mason et al., 1976). To illustrate, on the first day of starvation, 
food-deprived monkeys that could watch other monkeys being fed in nearby 
cages had an elevation of blood corticosteroids that occurred too early 
to be attributed to a physiological response due to a lack of food. 
However when the monkeys were carefully adapted to their surroundings, 
kept in a soundproof room, and maintained on regular "feeding" (non-
caloric, fruit-flavored pellets) schedules, there were none of the usual 
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changes in glucocorticosteroids associated with fasting periods. Mason 
concluded that there is a considerable degree of emotional disturbance, 
due to discomfort, inherent in the laboratory setting. Kidman (1984) 
expanded this idea to a "cognitive theory of stress" which says that, in 
spite of our best efforts to control hunger, temperature and other 
environmental pressures, we still become frustrated over perceived threats 
to our welfare and security. Thus, the stress response consists of a 
variety of physiological and psychological factors. These factors are 
most likely integrated through the central nervous system, in particular 
the hypothalamus, as it coordinates the interaction between the autonomic 
nervous system, the endocrine system and many forms of emotional behavior. 
3. Cardiovascular Changes in Response to Classical Conditioning 
Stressful conditions have been implicated in the etiology of 
cardiovascular disease and hypertension (Hollenberg et al., 1981; Manuck 
et al., 1981; Schulte et al., 1984). Changes in heart rate and arterial 
blood pressure can be classically conditioned (Dykman and Gantt, 1956). 
A neutral stimulus that elicits no cardiovascular response (conditioned 
stimulus) is paired with another stimulus (unconditioned stimulus) that 
evokes a vigorous cardiovascular response (unconditioned response). After 
several pairings of the conditioned and unconditioned stimulus, the 
previously neutral conditioned stimulus will eventually cause cardiovas-
cular changes in anticipation of the unconditioned stimulus (Cohen and 
Randall, 1984). 
Smith et al. (1984) have demonstrated that the perifornical area of 
the hypothalamus (referred to as HAGER, the Hypothalamic Area Controlling 
43 
Emotional Responses) is responsible for the cardiovascular responses that 
accompany emotional behavior in monkeys. Their operational definition of 
emotion included cardiovascular responses (elevated arterial blood 
pressure) and a behavioral response (suppression of lever pressing). 'When 
the hypothalamic area (HAGER) was electrically stimulated, it produced the 
same cardiovascular pattern as that associated with the emotional 
situation. The cardiovascular but not the behavioral portion of the 
emotional response was lost following ablation of the HAGER. Afferents 
to the HAGER include the amygdala and septal area as well as brain stem 
autonomic areas such as the central grey, nucleus tractus solitarius, and 
dorsal motor nucleus of the vagus. Efferents include a direct projection 
to the intermediolateral cell column cells of the thoracic cord, an 
important site with respect to sympathetic control of cardiovascular 
function. Other efferent projection sites include the raphe nuclei, the 
parabrachial complex, the hypothalamic PVN and the periaqueductal grey. 
Cardiovascular changes have been observed with the Sidman avoidance 
behavioral testing (Galosy et al., 1982). The Sidman avoidance paradigm 
(Sidman, 1953) is used frequently to evaluate cardiovascular changes 
associated with the postponement of electric shock contingent upon an 
appropriate reponse. The paradigm involves delivery of electric shock at 
regular intervals unless a response (such as lever pressing) occurs to 
delay the shock. If the animal presses the lever at least once during the 
interval, it can avoid all shocks (Turkkan et al., 1982). 
Anderson and Brady (1971, 1972) observed decreased heart rate and 
increased pulse and arterial blood pressure during the anticipatory pre-
avoidance period. Once the avoidance test was underway, the heart rate 
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rapidly increased above pre-avoidance levels while pulse and arterial 
blood pressure remained elevated. Further pharmacological studies 
indicated that the ~-adrenoceptor blocker propranolol partially attenuated 
the heart rate elevations during avoidance, but did not affect the 
increases in blood pressure in either avoidance or pre-avoidance periods 
(Anderson and Brady, 1976). In similar studies, the a-antagonist 
phenoxybenzamine blocked the elevation in blood pressure during the 
avoidance period but did not affect pre-avoidance changes in heart rate 
and arterial blood pressure (Anderson et al., 1976). From these and other 
studies, Galosy et al. (1982) suggested that reduced heart rate during the 
pre-avoidance period is dominated by parasympathetic mechanisms, whereas 
the arterial blood pressure levels may be mediated by peripheral vascular 
mechanisms which do not involve a receptors, perhaps cholinergically-
mediated shifts in blood flow (Anderson et al., 1976). During the 
avoidance period, a combination of increased sympathetic and decreased 
parasympathetic activity leads to increased heart rates, while elevated 
arterial pressure is due to continued sympathetic peripheral vasoconstric-
tion (Galosy et al., 1982). 
In humans, the stress response, as elicited by a demanding 
arithmetic test (Brod et al., 1959), consisted of the following: 
vasodilatation in skeletal muscle, coronary vessels and brain, while most 
other resistance vessels and veins underwent a neurogenic vasoconstric-
tion. Increased sympathetic and decreased parasympathetic influences on 
the heart resulted in tachycardia, increased cardiac ouput and slightly 
increased mean arterial pressure. Neuroendocrine responses included 
increased epinephrine, ACTH, corticosteroids, vasopressin and renin-
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angiotensin-aldosterone by means of sympathetic nerve stimulation of the 
kidney (Brod, 1970). Brod et al. (1962) demonstrated that this cir-
culatory pattern exists in hypertension, especially the early stages. 
Eliasson (1984) observed that the limbic-hypothalamic pattern of stress 
responses is nearly identical in animals and man. He proposed that modern 
humans develop hypertension because they are socially deprived of the 
acting-out behavior which is a large part of the stress or defense 
reaction. However, the autonomic and hormonal changes associated with 
the stress reaction are not suppressible, therefore hypertension results. 
4. Neuroendocrine Changes in Response to Stress 
a. Stress-Induced Renin Secretion 
The physiological response to stress involves the release of 
catecholamines from the adrenal medulla and sympathetic nerve endings. 
Stimulation of the renal nerves increases renin secretion (Di Bona, 1985; 
Blair et al., 1985), and this stimulatory effect is mediated, at least in 
part, via norepinephrine released at the endings of the postganglionic 
sympathetic neurons that innervate the kidneys (Davis and Freeman, 1976; 
Reid et al, 1978; Ganong and Barbieri, 1982). Circulating epinephrine and 
norepinephrine can also stimulate renin secretion. 
Many investigators have reported increases in plasma renin activity 
in response to a variety of stressors. Clamage et al. (1976) reported 
increases in plasma renin activity in rats following 30 minutes exposure 
to either novel "open field" environment or the presence of a hungry cat. 
Jindra et al. (1980) observed increases in plasma renin activity after 
acute and repeated immobilization stress. Paris et al. (1987) reported 
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increased plasma renin activity by the following stressors: 12 minute 
conditioned fear paradigm; 20 minute immobilization; 20 minute forced 
swimming in cold water; 2, 12 and 22 minutes of intermittent footshock; 
and a 3 minute conditioned fear paradigm with 0, 10, 30 and 60 minute 
recovery. Blair et al. (1976) reported an elevation of plasma renin 
activity in baboons during avoidance performance. Gotoh et al. (1985) 
demonstrated that bilateral knife cuts behind the hypothalamic paraven-
tricular nucleus (PVN) reduced the renin response to immobilization and 
the gravitational stress of head-up tilting. Plasma renin activity 
clearly can be increased by many different types of stressors. 
Sigg et al. (1978) found that restraint causes an increase in plasma 
renin activity which was not blocked by pretreatment with the &-adrenergic 
antagonists dl-propranolol or sotalol. However, propranolol pretreatment 
prevented the increase in plasma renin activity following swim stress and 
ether stress (Pettinger et al., 1972) and intermittent footshock (Leenen 
and Shapiro, 1974). Also, Van de Kar et al. (1985) have shown that 
propranolol significantly inhibits the increase in plasma renin activity 
following a three-minute conditioned fear paradigm. Evidence for a role 
of central catecholamines in stress-induced renin secretion was provided 
by Lightman et al. (1984) who demonstrated that injections of the 
catecholamine neurotoxin 6-0HDA into the dorsal noradrenergic bundle 
markedly attenuated the increase in plasma renin activity in response to 
hemorrhage. Kobayashi et al. (1975) have reported that afferent fibers 
from the locus coeruleus to the PVN travel in the dorsal noradrenergic 
bundle. These studies suggest that central catecholaminergic projections 
to the PVN may be involved in the renin response to stress. 
b. Stress-Induced Corticosterone Secretion 
1. Introduction 
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Corticosterone levels have been shown to increase in response to 
several stressors. For example, Armario et al. (1986) demonstrated that 
the corticosterone response to stress is directly related to the intensity 
of the stress stimulus. The stressors used in their study were graded 
levels of low intensity stressors (either transfer to a novel cage or 
room, or a loud noise). These results are in agreement with findings by 
Kant et al. (1983), who demonstrated that increases in plasma cor-
ticosterone levels were related to the intensity of footshock. They found 
that corticosterone secretion was very sensitive not only to an obvious 
stressor (footshock) but also to any change in the environment accompany-
ing the procedure. Simply placing the rat in the shock box without 
delivery of any current elicited a strong corticosterone response. These 
studies suggest that the increase in corticosterone levels in response to 
stress can represent a sensitive index of the intensity of emotional 
arousal experienced by the animals. 
Dohanics et al. (1986) found that the adrenocortical response to 
ether stress occurs independently of neurohypophyseal function, and that 
the full corticosterone and ACTH response to ether or ether plus 
laparotomy stress requires not only an intact PVN but also an intact 
neurointermediate lobe. 
2. Stress-Induced Secretion of CRF 
CRF has been shown to mediate stress-induced ACTH release in rats 
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(Rivier and Vale, 1983). CRF also has been shown to initiate other 
biological actions in response to stress. For example, injections of CRF 
into the cerebral ventricles produced significant increases in plasma 
concentrations of epinephrine, norepinephrine, glucagon and glucose, 
elevated mean arterial pressure and heart rate, and inhibited gastric acid 
secretion. Pretreatment with the ganglionic blocking drug chlorisondamine 
completely abolished the increases in plasma catecholamines and glucose, 
heart rate and blood pressure (Lenz et al., 1987). CRF has been shown to 
activate brain catecholamine systems. Studies by Dunn and Berridge (1987) 
demonstrated that injections of CRF into the cerebral ventricles of mice 
resulted in increased dihydroxyphenylacetic acid (DOPAC):dopamine ratios 
in prefrontal cortex, septum, hypothalamus and brain stem compared to 
saline controls. The ratio of 3-methoxy-4-hydroxyphenylethyleneglycol 
(MHPG):norepinephrine was increased in the prefrontal cortex and 
hypothalamus. DOPAC and MHPG are the major catabolites of dopamine and 
norepinephrine, respectively. CRF release has been measured in conscious, 
unrestrained rats using a push-pull cannula system implanted in the median 
eminence (Ixart et al., 1987). Basal CRF release occurs in a pulsatile 
pattern with peaks about every 45 minutes (peak mean 9.0 ± 0.7 pg vs. 
trough 4.1 ± 0.3 pg). Ether elicited an increase in CRF which lasted 
about 45 minutes with peak values of 54.3 ± 3.2 pg. 
3. Stress-Induced Secretion of ACTH 
Gibbs (1984) found that ACTH secretion increased in response to 
restraint, cold or ether stress. However, Armario et al. (1985) have 
found dissociations between ACTH and corticosterone responses: the ACTH 
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response to restraint stress, unlike the corticosterone response, was the 
same in control and in chronically stressed rats. This suggests that the 
increased corticosterone levels from restraint stress are not necessarily 
due only to increased pituitary ACTH release. 
The increase in ACTH following hemorrhage was prevented by PVN 
lesions, while the responses of renin, epinephrine, norepinephrine, mean 
arterial blood pressure and heart rate to hemorrhage were not affected 
(Darlington et al., 1988). However, these lesions consisted of creating 
an island of the PVN and dorsal hypothalamus by lowering a triangular 
(Halasz-type) knife into the third ventricle to the level of the PVN and 
then rotating. This may have disrupted fiber pathways to and from the 
PVN without actual damage to PVN cell bodies. 
Makara et al. (1986) proposed that ACTH hypersecretion following 
adrenalectomy is driven primarily by CRF- and/or vasopressin-producing 
neurons in and around the PVN, while either (a) other sources of CRF-41, 
(b) increased pituitary sensitivity, or (c) other hypothalamic factors 
may restore the stress-induced ACTH release in the absence of the PVN. 
The effect of bilateral lesions of the PVN on circadian rhythm and 
ether stress responsiveness of plasma ACTH and corticosterone were studied 
in chronically cannulated female Sprague-Dawley rats. Three weeks after 
PVN lesions, ACTH values had dropped by at least half, and the diurnal 
maximum and amplitude for corticosterone were diminished by one third. 
The peaks for both hormones following ether stress were only half as high 
as the control peaks (Ixart et al., 1982). These results support the role 
of the PVN as a mediator of stress- induced ACTH and corticosterone 
secretion. 
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4. Role of Vasopressin in Stress-Induced Corticosterone Secretion 
Vasopressin promotes the retention of water by the kidney, to 
maintain plasma volume. There are two major vasopressin systems in the 
hypothalamus. One system has cell bodies in the PVN and supraoptic 
nuclei, projecting through the internal zone of the median eminence to 
the pars neuralis of the pituitary gland. The other system consists of 
cell bodies in the PVN with nerve terminals in the median eminence 
(Silverman and Zimmerman, 1983). One difference between these systems is 
that adrenalectomy resulted in increased staining intensity of vasopressin 
immunoreactive nerve fibers in the external zone of the median eminence, 
whereas the fibers of the neural lobe or intenal zone of the median 
eminence were not affected (Zimmerman et al., 1977). 
Vasopressin has been shown by Tilders et al. (1985) to have an 
important role in the stress-induced activation of the pituitary-adrenal 
system, possibly by potentiating the effects of CRF. Pretreatment of rats 
with an antiserum to vasopressin inhibited the ACTH response to both 
restraint and formalin stress. Vasopressin has also been shown to 
potentiate the activity of CRF (Gillies et al., 1982). Vasopressin 
secretion is stimulated by hemorrhage (Robertson, 1977), hypoglycemia 
(Bayliss and Robertson, 1980), electric shock (Husain et al., 1979) and 
ether (Gibbs, 1984). 
Further evidence for the involvement of vasopressin in the ACTH 
response to stress is that the vasopressin antagonist dpTyr(Me)arginine 
vasopressin decreases ether stress-induced ACTH release, and administra-
tion of both the vasopressin antagonist and CRF antiserum completely 
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prevented stress-induced ACTH secretion (Rivier and Vale, 1983). However, 
some studies reported that dpTyr(Me)arginine vasopressin does not block 
either the intrinsic ACTH-releasing activity or its synergistic effects 
with CRF (Baertschi et al., 1984; Knepel et al., 1984) and, therefore, 
should be avoided in studies involving ACTH release (Tilders et al., 
1985). 
5. Role of Catecholamines in Stress-Induced Corticosterone 
Secretion 
Controversy still exists as to whether catecholamines play an 
excitatory or inhibitory role in stress-induced corticosterone secretion. 
i. Evidence for an Inhibitory Role of Catecholamines 
Brain norepinephrine has been postulated to inhibit ACTH secretion 
(van Loon et al., 1971; Weiner and Ganong, 1978). Eisenberg (1975) 
administered reserpine (systemically) or phenoxybenzamine (centrally) and 
found an augmentation of the plasma corticosterone response to ether. 
This suggests that norepinephrine may function in the central nervous 
system to inhibit the stress response. However, reserpine is not a 
selective noradrenergic depletor as it will also deplete serotonin stores 
(Bugnon et al., 1983). 
Suemaru et al. (1985) observed significant increases in serum ACTH 
and corticosteorne levels 15 minutes after the onset of either ether-
laparotomy or cold-restraint stress. The hypothalamic CRF concentration 
showed a rapid increase 2.5 minutes following ether-laparotomy stress, 
followed by a significant decrease after 15 minutes, and a subsequent 
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increase. Norepinephrine concentration in the hypothalamus was reduced, 
whereas dopamine concentration was increased. Epinephrine concentrations 
did not show a significant change throughout the stress procedure. From 
these observations they concluded that norepinephrine in the hypothalamus 
may not be involved in stimulating hypothalamic CRF secretion in the early 
phase of acute stress. 
Glavin et al. (1985) depleted brain norepinephrine in rats by 
injecting the dopamine-E.-hydroxylase inhibitor FI.A-63 (to prevent the 
conversion of dopamine to norepinephrine) followed by R04-1284, a 
reserpine-like vesicular depletor of norepinephrine, dopamine and 
serotonin. This treatment produced significant depletion of norepineph-
rine in all brain regions examined. Norepinephrine depletion did not 
prevent the increase in plasma corticosterone levels following cold-
restraint stress. However, in the non- stressed rats, there was no 
significant difference in plasma corticosterone levels between the 
norepinephrine-depleted and saline-treated rats. The authors suggest that 
norepinephrine does not mediate cold restraint stress-induced increases 
in plasma corticosterone levels, nor does it play an inhibitory role with 
respect to corticosterone secretion. However, this study combines two 
non-related stimuli (cold vs. immobilization) as stressors without 
addressing how this could affect hormonal responses. 
Reinstein et al. (1985) have demonstrated that acute, uncontroll-
able stress (restraint and intermittent footshock for one hour) depleted 
norepinephrine in the rat brain (increased norepinephrine turnover). 
Pretreatment with supplemental tyrosine (to prevent norepinephrine 
depletion) prevented hypothalamic norepinephrine depletion and suppressed 
53 
the increase in plasma corticosterone, suggesting an inhibitory role for 
norepinephrine. However, these corticosterone data were reported as 
percent of non-stressed control values, which were quite high (37 .4 
ug/dl). In conclusion, there is weak evidence in these studies to support 
an inhibitory role for norepinephrine in corticosterone secretion. 
ii. Evidence for a Stimulatory Role of Catecholamines 
in Stress-Induced Gorticosterone Secretion 
Gibson et al. (1986) found that bilateral injections of 6-0HDA into 
the PVN prevented the restraint stress-induced increase in plasma 
corticosterone levels. Pretreatment with the a 1-adrenoceptor antagonist 
prazosin, at a dose which did not influence resting hormone levels, 
inhibited the increase in plasma corticosterone following restraint 
stress. The authors suggest an excitatory role for norepinephrine via a 
receptors in CRF release during acute stress. Similarly, Feldman et al. 
(1986) injected 6-0HDA into the PVN and found that PVN norepinephrine 
depletion did not affect basal levels or ether stress-induced increases 
in corticosterone levels, but it did significantly inhibit the adrenal 
response to photic and acoustic stimuli and sciatic nerve stimulation, 
suggesting that noradrenergic terminals in the PVN play a role in the 
activation of adrenocortical responses following afferent neural stimuli. 
Smythe et al. (1983) support the hypothesis that stress-induced ACTH 
release from the pituitary is stimulated by hypothalamic noradrenergic 
neuronal pathways. They measured norepinephrine activity in the 
mediobasal hypothalamus by assessing the ratio of 3,4-dihydroxyphenyl-
ethyleneglycol (DHPG) /norepinephrine. Hypothalamic norepinephrine 
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activity was rapidly increased by cold swim stress in the rat, accompanied 
by increased ACTH/corticosterone release into the blood. Norepinephrine 
activity and ACTH release were also stimulated in rats following ether 
stress. The significant correlation between serum corticosterone and the 
ratio of hypothalamic DHPG/norepinephrine (shown by linear regression 
analysis of the combined data for control and stressed rats in their 
studies) is not evidence, but suggests that hypothalamic norepinephrine 
neuronal activity may play an important stimulatory role in stress-induced 
ACTH release. 
Studies by Johnston et al. (1985) support the data presented by 
Smythe et al. (1983). Norepinephrine, dopamine and 5-HT concentrations 
as well as the concentrations of their respective metabolites MHPG, DOPAC 
and 5-hydroxyindole-3-acetic acid (5-HIAA) were measured by HPLC. The 
metabolism of norepinephrine, dopamine and 5-HT in different rat brain 
nuclei was estimated by the ratio of the metabolite to its respective 
amine. Ether stress produced large increases in plasma ACTH, accompanied 
by significant increases in norepinephrine metabolism in the PVN, arcuate 
and dorsomedial nuclei. Serotonin metabolism was decreased in the PVN, 
supraoptic nucleus and caudal division of the arcuate nucleus, while 
significant increases in 5-HT metabolism were detected in the suprachias-
matic nucleus and rostral division of the arcuate nucleus. Dopamine 
metabolism was selectively increased in the rostral division of the 
arcuate nucleus. The authors interpret the data as suggesting a 
stimulatory role for norepinephrine, possibly in the PVN with respect to 
ACTH secretion. 
Studies by Mermet and Gonon (1988) used differential normal-pulse 
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voltammetry combined with carbon fiber electrodes to measure in vivo 
extracellular catechols released by noradrenergic nerve terminals in the 
PVN. In rats pretreated with the monoamine oxidase inhibitor pargyline, 
ether stress produced an increase in the catechol signal corresponding to 
extracellular norepinephrine. Electrical stimulation of the ventral 
noradrenergic bundle also caused an immediate increase in the signal. 
The increase in norepinephrine release following ether stress was 
immediate and lasted as long as the stimulus duration. No dopamine 
release was recorded from either the striatum or the Al3 dopaminergic cell 
body group caudal to the PVN. These data suggest a facilitatory action 
of norepinephrine on PVN cell bodies which are involved in the hormonal 
responses to stress. 
Immobilization stress (varying from 15 to 180 minutes) significant-
ly increased MHPG-S04 levels and decreased norepinephrine levels in the 
following rat brain regions: hypothalamus, amygdala, hippocampus, 
thalamus, pons, medulla and cerebral cortex, with the most rapid and 
profound increase in MHPG-S04 found in the hypothalamus. However, the 
basal ganglia demonstrated the reverse process- increases in norepineph-
rine levels with transient decreases in MHPG-S04 levels. There was a 
concomitant increase in plasma corticosterone levels following immobiliza-
tion stress (Tanaka et al., 1982). This study suggests that norepineph-
rine released in the hypothalamus during immobilization stress may play 
a role in the stress-induced increase in corticosterone levels. 
Beaulieu et al. (1987) demonstrated that bilateral lesions of the 
central nucleus of the amygdala significantly inhibited the stress-induced 
ACTH secretion following immobilization. These lesions also reduced the 
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stress-induced noradrenergic activity in the anterior and lateral 
hypothalamic areas, the PVN and arcuate nucleus, and the bed nucleus of 
the stria terminalis. These results suggest that norepinephrine plays a 
stimulatory role in ACTH secretion and is somehow regulated by neurons in 
the central nucleus of the amygdala. 
As stated earlier, the ventral noradrenergic bundle (VNAB) is 
thought to be the source for the noradrenergic modulation of ACTH 
secretion (see CORTICOSTERONE: Role of the VNAB). Szafarczyk et al. 
(1985) have shown that injection of 6-0HDA into the VNAB obliterates the 
circadian patterns for ACTH and corticosterone secretion, and also caused 
an 80% inhibition of the ACTH response to stress. 
Injections of 6-0HDA into the VNAB also prevented the increase in 
corticosterone secretion following exposure to photic and acoustic stimuli 
and sciatic nerve stimulation (Feldman et al., 1988). However, basal 
levels of corticosterone and ether-induced increases in corticosterone 
were not affected. The 6-0HDA-injected rats had average norepinephrine 
depletions of 72% in the mediobasal hypothalamus and 78% in the paraven-
tricular nucleus when compared to vehicle-injected rats. These data 
support previous studies (Feldman et al., 1986) in which 6-0HDA injections 
into the PVN did not affect basal levels or ether-induced increases in 
corticosterone levels, but did significantly inhibit the adrenal response 
to photic and acoustic stimulation and sciatic nerve stimulation. These 
studies suggest that norepinephrine plays a role in the activation of 
adrenocortical responses following afferent neural stimuli. 
In contrast, Velley et al. (1988) have shown that 6-0HDA lesions 
in the locus coeruleus did not prevent the effect of novel environment 
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stress on corticosterone, although there was a significant (53%) depletion 
of hypothalamic norepinephrine. However, this can be explained by the fact 
that about 90% of the norepinephrine supply to the PVN originates from the 
lower brainstem Al and A2 cell groups, while the locus coeruleus 
projection to the PVN is only about 8% (Sawchenko and Swanson, 1982). 
iii. Role of Epinephrine in Stress-Induced 
Corticosterone Secretion 
Szafarczyk et al. (1987) demonstrated a stimulatory role for 
epinephrine (and norepinephrine) on corticosterone release when 
intracerebroventricular (icv) injections of epinephrine or norepinephrine 
induced ACTH release comparable to that occurring under conditions of 
ether stress. Epinephrine was more efficacious than norepinephrine on an 
equimolar basis. The stimulating effect of norepinephrine was reversed 
by icv pretreatment with prazosin, an a 1- adrenoceptor antagonist, whereas 
the effect of epinephrine was inhibited by either prazosin or the .&-
blocker propranolol. These results suggest that norepinephrine triggers 
ACTH release via a1-adrenoceptors, whereas epinephrine acts via both a 1-
and B-adrenoceptors. It should be noted that they also administered a 
combined pretreatment of prazosin and propranolol, and this combined 
treatment was no more effective than either antagonist alone. They also 
demonstrated that a unilateral juxta-PVN injection of either epinephrine 
or norepinephrine produced an increase in plasma ACTH concentration with 
a time course similar to that for an icv injection, and pretreatment with 
anti-rCRF-41 serum caused a 50-60% reduction in the ACTH response to 
either catecholamine. Since the majority of diencephalic CRF neurons are 
58 
located in the parvocellular subnuclei of the PVN (Swanson et al., 1983; 
Liposits et al., 1985), these data suggest a role for a 1 and B receptors 
in the PVN in the regulation of corticosterone secretion. 
Additional evidence was obtained by Spinedi et al. (1988) who 
demonstrated that central inhibition of the enzyme that converts 
norepinephrine to epinephrine, phenylethanolamine-N-methyltransferase 
(PNMT), produced a selective decrease in hypothalamic epinephrine levels, 
significantly decreased the plasma ACTH response to ether stress, and at 
later times also caused a selective decrease in CRF content. In addition, 
the altered ACTH response to ether stress was not due to changes in 
arginine vasopressin levels or changes in pituitary responses to CRF. 
These results support a stimulatory role of central epinephrine neurons 
on CRF release. 
6. Role of Serotonin (5-HT) in Stress-Induced 
Corticosterone Secretion 
The role of serotonin as a mediator of stress-induced corticosterone 
secretion is not clear. Electrolytic lesions in the dorsal raphe nucleus 
prevented the stress-induced increase in corticosterone levels as well as 
increases in plasma renin activity and plasma renin concentration 
following a ten-minute conditioned fear paradigm (Richardson Morton et 
al., 1986). Other studies from our laboratory have shown that injection 
of the neurotoxin 5,7-dihydroxytryptamine into the dorsal and median raphe 
nucleus did not prevent the stress-induced increase in renin and 
corticosterone secretion. Furthermore, i. p. injection of the 5-HT2 
antagonist LY53857 did not prevent the stress-induced increase in renin 
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and corticosterone secretion (Richardson Morton et al., 1986), whereas low 
doses of the 5-HT1 agonist buspirone and ipsapirone inhibited the stress-
induced increase in corticosterone and renin secretion (Van de Kar et al., 
1985; Urban et al., 1986; Lorens et al., 1989). These studies suggest 
that a non-serotonergic (or possibly 5-HT1) mechanism is involved in 
stress-induced renin and corticosterone secretion. 
Feldman et al. (1987) reported that injection of the serotonergic 
neurotoxin 5, 7-dihydroxytryptamine (5, 7-DHT) into the PVN blocked the 
adrenocortical responses to cortical and extra-hypothalamic limbic 
stimulation, but had no effect on the adrenocortical response to ether 
stress. Immobilization and cold-exposure stress resulted in four-fold 
increases in ACTH-like imrnunoreactivity in plasma. This increase was 
potentiated by i.p. injections of the 5-HT reuptake inhibitor fluoxetine 
and significantly reduced by the 5-HT antagonists metergoline and 
cinanserin (Bruni et al., 1982). These results suggest that 5-HT may play 
a role in stress-induced ACTH release. In contrast, Fuller and Snoddy 
(1977) found that pretreatment with fluoxetine did not significantly alter 
the increase in plamsa corticosterone levels following swim stress or 
insulin-induced hypoglycemia. However, fluoxetine did enhance the 
corticos terone response produced by an inj ec ti on of L- 5-hydroxytryptophan. 
These results suggest that serotonergic neural pathways are involved in 
mediating the adrenocortical response to some stressful stimuli (i-
mmobilization and cold exposure) but not others (swim stress and insulin-
induced hypoglycemia). 
Beaulieu et al. (1986) support the studies by Bruni et al. (1982). 
They found that bilateral lesions of the central nucleus of the amygdala 
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resulted in significantly decreased immobilization stress-induced ACTH 
secretion with a concomitant increase in serotonergic activity in the PVN 
and arnygdaloid nuclei. Additional studies by Beaulieu et al. (1987) 
suggest a serotonergic involvement in immobilization stress. In these 
studies, bilateral lesions of the central nucleus of the amygdala in 
unstressed rats increased the serotonergic activity in the PVN, dor-
somedial nucleus, anterior hypothalamic area (AHA), cortical and medial 
amygdaloid nuclei, and the lateral part of the basal amygdaloid nucleus. 
Immobilization stress applied to lesion rats resulted in a decrease in 
serotonergic activity to control levels in the PVN, AHA and the dor-
somedial nucleus, and below control levels in the ventromedial nucleus. 
The serotonergic activity remained elevated in each of the amygdaloid 
areas measured, which are rich in glucocorticoid receptors (Beaulieu et 
al., 1986). Glucocorticoids have been reported to down-regulate their own 
receptors in a site-specific manner in the amygdala, septum and hippocarn-
pus, but not in the hypothalamus or pituitary (Sapolsky et al., 1984). 
Also noradrenergic cell bodies (Al-A7), serotonergic cell bodies (Bl-B9), 
and PNMT-immunoreactive nerve cells of the adrenergic cell groups (Cl-C3) 
have been shown to have strong glucocorticoid receptor immunoreactivity 
(Harfstrand et al., 1986). De Kloet et al. (1986) have shown that 
corticosterone selectively controls the 5-HT1 receptor density in the 
dorsal raphe and dorsal hippocampus. These studies suggest that serotonin 
may modulate the negative feedback of glucocorticoids on stress-induced 
ACTH secretion. A moderate to strong nuclear glucocorticoid receptor 
immunoreactivity has been demonstrated in the majority of CRF-immunoreac-
tive neurons of the parvocellular PVN, septohypothalamic thalamus, bed 
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nucleus of the stria terminalis, and the medial and central amygdaloid 
nuclei (Cintra et al., 1987). 
C. Effect of Peripheral Sympathectomy on Stress-Induced Renin and 
Corticosterone Secretion 
The physiological response to stress involves the release of 
catecholamines from the adrenal medulla and sympathetic nerve endings. 
These catecholamines stimulate the renal nerves to increase renin output. 
It is generally accepted that the sympathetic nervous system mediates the 
stress response from the brain to the kidney (Golin et al., 1988; Reid et 
al., 1978). Studies by Van de Kar et al. (1985) have shown that the &-
adrenoceptor antagonist propranolol significantly inhibits but does not 
completely block the stress-induced increase in plasma renin activity. 
It should be noted, however, that this effect could be mediated by either 
central or peripheral &-receptors since propranolol is known to cross the 
blood brain barrier (Giarcovich et al., 1984; Lemmer et al., 1985). To 
determine whether stress-induced renin secretion is mediated by the 
peripheral sympathetic nervous system, rats were adrenal enucleated and 
given weekly injections of 6-0HDA (i.p.). The adrenal medulla was removed 
since it does not effectively take up 6-0HDA. The effectiveness of the 
sympathectomy/adrenal enucleation was verified by determination of plasma 
epinephrine (less than 1% of control) and norepinephrine (less than 10% 
of control). The stressor induced a significant increase in plasma renin 
activity and concentration. Sympathectomized-adrenal enucleated rats 
showed no inhibition of the stress - induced increase in plasma renin 
activity/concentration or plasma corticosterone levels (Richardson Morton 
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et al., 1988). The data suggest that the sympathetic nervous system and 
adrenal catecholamines are not the only mediators of the stress-induced 
increase in renin secretion. 
5. Central Nervous System Pathways Involved in the 
Stress Response 
a. Sensory Afferents 
With respect to the role of the central nervous system in the 
conditioned fear response, it is important to consider how the sensory 
stimulus (pain) is transmitted to the cerebral cortex for analysis. 
Specialized nerve fibers found throughout the skin serve as end organs 
for pain. These fibers enter the spinal cord and ascend through the 
lateral spinothalamic tract to the posteroventral nucleus of the thalamus. 
From here the fibers travel to the appropriate loci in the cerebral 
cortex, depending on the somatic origin of the pain message. 
The ascending reticular activating system (ARAS) is a network of 
interconnective fibers that also travel from the top of the spinal cord 
to the thalamus, and eventually to the cortex. This tract receives major 
sensory inputs, and conveys information regarding alertness and excite-
ment. 
There appears to be a close connection between pain sensation and 
the ARAS. The midbrain and brainstem reticular formations receive many 
pain afferents from the spinothalamic tract. Studies in animals (Olds 
and Olds, 1965) and humans (Gray, 1971) have suggested that stimulation 
through electrodes in the periventricular midbrain reticular system 
generates pain sensation. Other pain reception fibers have been found in 
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the thalamic portion of the ARAS. Lesions in the thalamic intralaminar 
nuclei and the thalamic nucleus centrum medianum have been shown to 
alleviate intractable pain in humans (Gray, 1971). 
b. The Limbic System 
1. Septo-Hippocampal System 
The limbic system, in particular the septo-hippocampal system, 
appears to play a major role in pain reception. The hippocampus emits a 
theta wave (4-9 cps rhythm) as a response to a painful stimulus in the 
rat, and in the emotional states of disappointment and frustration in 
humans (Gray, 1971). This theta wave can be abolished by lesions in the 
medial nuclei of the septum, and the thalamic nucleus centrum medianum, 
suggesting that the pain input route most likely travels from the midbrain 
reticular formation, through the thalamus, to reach the septum and 
hippocampus (Gray, 1971). 
2. Amygdala 
The amygdala is a limbic structure with many interconnections to the 
hippocampus (Krettek and Price, 1978). The amygdaloid complex has been 
shown to be involved in the regulation of fear-motivated behavior 
(Blanchard and Blanchard, 1972; Spevack et al., 1975). In addition, the 
amygdala appears to play a role in the stress response via the pituitary-
adrenal cortical axis. The central nucleus of the amygdala, in par-
ticular, contains large numbers of CRF-containing cell bodies and 
terminals (Swanson et al., 1983; Moga and Gray, 1985). Injection of CRF 
into the lateral ventricles of rats or dogs elicits autonomic and 
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behavioral changes that are characteristic of the stress or defense 
reaction (Brown et al., 1982; Lenz et al., 1987; Britton 
et al., 1982). Electrical stimulation of the amygdaloid complexes results 
in an increase in adrenal glucocorticoid secretion in rats (Redgate and 
Fahringer, 1973), cats (Redgate, 1970) and monkeys (Mason, 1959). The 
amygdaloid complex is an essential part of the ACTH controlling mechanism 
in rats (Knigge, 1961; Allen and Allen, 1974). Specifically it has been 
shown to be necessary for the hypersecretion of ACTH following adrenalec-
tomy (Allen and Allen, 1975). In these studies, lesions which destroyed 
the direct medial-projecting amgdalo-hypothalamic fibers blocked the 
hypersecretion of ACTH following adrenalectomy, while lesions of the 
septal region, stria terminalis and fornices did not. 
Lesions in the amygdaloid central nucleus impaired one-way active 
avoidance learning (Werka et al., 1978), produced marked deficits in 
passive avoidance performance (Mcintyre and Stein, 1973; Grossman et al., 
1975), and significantly decreased ACTH secretion in response to 
immobilization stress (Beaulieu et al., 1987). Axons from cells in the 
olfactory bulb terminate in the amygdala (Powell et al., 1965) and the 
medial hypothalamus receives axons from cells in the amygdala (Cowan et 
al., 1965). Bilateral amygdalectomy significantly reduced the adrenocor-
tical responses to sciatic nerve and olfactory stimulation, without 
affecting the corticosterone response to ether or to photic and acoustic 
stimulation (Feldman and Conforti, 1981). This amygdalo-hypothalamic 
pathway is believed to play a role in the adrenocortical response to a 
number of somatosensory stimuli (Feldman et al., 1975). The amygdala has 
also been shown to play an important role in regulating the cardiovascular 
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system during Sidman avoidance stress testing (Galosy et al., 1982). 
3. Hypothalamic Ventromedial Nucleus 
With respect to the central neural circuits involved in the 
fight/flight behavior, de Molina and Hunsperger (1962) described a pathway 
in cats that descends from the amygdala along the stria terminalis to the 
ventromedial hypothalamus (VMN) with connections to the midbrain central 
grey. Stimulation of sites within the hypothalamus, amygdala and midbrain 
central grey could produce defensive attack while other loci immediately 
adjacent to those stimulated would produce flight. When the VMN was 
removed, stimulation of the amygdala no longer produced defensive attack, 
and removal of the central grey prevented the flight behavior following 
hypothalamic stimulation. 
In addition, Kling et al. (1958) reported that cats made docile by 
lesions in the amygdala could be made ferocious by subsequent lesions in 
the VMN. The converse did not apply - cats first made ferocious by 
lesions in the hypothalamus were not affected by a subsequent amygdalec-
tomy. 
Based on these and other observations, Gray (1971) suggested that 
the midbrain central grey is the ultimate controlling area for either 
flight or defensive behavior. In addition, there is a tonic inhibitory 
input to the central grey from the VMN. Further modulation of this 
inhibitory input would come from the amygdala and the septo-hippocampal 
system. Input from the amygdala would prevent the inhibition, resulting 
in fight/flight behavior, and the septo-hippocampal input would intensify 
passive avoidance behavior. The resulting behavior (either passive 
66 
avoidance or fight/flight) would depend on which of the inputs to the VMN 
is stronger under a particular set of environmental conditions. This 
scheme would provide a basis for the observation that, in times of danger, 
both freezing and fight/flight patterns may be stimulated simultaneously 
and alternate rapidly with each other. 
Neurons in the VMN have been shown to play a role in stress-induced 
renin secretion. Gotoh et al. (1988) found that bilateral electrolytic 
lesions in the VMN prevented the increase in plasma renin activity 
following immobilization stress. Lesions in the VMN led to excessive 
levels of food intake and adiposity (Hetherington and Ranson, 1942), and 
elicited a variety of metabolic and behavioral disturbances termed the VMN 
syndrome, which has become a model for the study of obesity and motivated 
behavior (Weingarten et al., 1985; Stellar, 1954). 
c. Role of Brain Catecholamines in Stress 
A variety of stressors including foot shock (Bliss et al., 1968; 
Thierry et al., 1968, Iimori et al., 1981), immobilization (Corrodi et 
al., 1968; Tanaka et al., 1981) and ether stress (Vellucci, 1977) have 
been shown to decrease norepinephrine concentration and increase 
norepinephrine turnover in the rat brain. 
The metabolism of norepinephrine in the rat brain results in the 
production of the sulfate conjugates MHPG-S04 , the major metabolite, and 
DHPG-S04 (Schanberg et al., 1968; Sugden and Eccleston 1971). The 
functional activity of central noradrenergic neurons has been shown to be 
directly related to the production of MHPG-S04 (Stone, 1975). Levels of 
MHPG-S04 in rat brain represent a useful index for norepinephrine turnover 
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in discrete brain regions (Kohno, 1981) as well as in the whole brain 
(Korf et al., 1973; Stone, 1976). 
Rats subjected to a mild psychological stressor (exposure to 
responses of shocked rats) had decreased norepinephrine and increased 
MHPG-S04 concentrations preferentially in the hypothalamus and amygdala. 
Rats subjected to footshock stress had decreased norepinephrine and 
increased MHPG-S04 not only in the hypothalamus and amygdala but also the 
pons, medulla oblongata and cerebral cortex (Iimori et al., 1981). This 
study suggests that the noradrenergic response to stress varies with the 
nature or intensity of the stressor. 
Brain noradrenergic systems, in particular the locus coeruleus-
noradrenergic system, have been shown to play a role in nociception, 
anxiety and fear (Charney and Redmond, 1983). The locus coeruleus 
receives innervation from sensory (pain) pathways in the spinal cord, and 
relays information to the cerebral cortex and limbic structures (hypothal-
amus, hippocampus, amygdala) (Kuhar, 1986). 
Rasmussen and Jacobs (1986) have recorded the electrical activity 
of noradrenergic neurons in the locus coeruleus of freely moving cats. 
During GER training, locus coeruleus units showed a large increase in 
activity in response to a stimulus paired with a noxious air puff, whereas 
no increase in unit activity is seen in response to a stimulus not paired 
with the air puff. Also, electrical stimulation of the locus coeruleus 
in monkeys elicited behavioral responses identical to those seen in 
experimentally-induced or naturally-occurring fear states (Bertrand, 
1969). 
In humans, drugs that increase noradrenergic function have been 
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shown to produce anxiety. The a 2-adrenoceptor antagonists yohimbine and 
piperoxane induced anxiety states in normal subjects (Soffer, 1954; 
Holmberg and Gershon, 1961). These studies support the role of brain 
norepinephrine in mediating the response to anxiety and fear. 
The Kety hypothesis (Kety, 1970) proposed that forebrain nor-
epinephrine enhances cell firing in neurons that receive afferent 
environmental information to "affectively important events". Further, 
norepinephrine would produce a "persistent facilitation" of these inputs 
which would reinforce the memory process for these events. The extensive 
innervation of the limbic system (especially the hippocampus) by the locus 
coeruleus-norepinephrine system suggests that noradrenergic neurons may 
play a role in the memory or cognitive process of stress. 
D. HYPOTHALAMIC PARAVENTRICULAR NUCLEUS (PVN) 
A. Introduction 
The PVN is a bilateral, triangular-shaped nucleus at the dorsal 
end of the third ventricle in the hypothalamus. It is a morphologically 
complex structure, with eight clearly distinguishable subdivisions, which 
contain as many as thirty different putative neurotransmitters. Three 
major efferent projection sites, arising from separate neuron groups, 
include (1) the median eminence, (2) the posterior pituitary and (3) the 
autonomic centers in the brain stem and spinal cord (Swanson and 
Sawchenko, 1983; Saper et al., 1976). This suggests that the PVN serves 
as an integrator of endocrine, autonomic and behavioral functions in a 
variety of physiological systems. 
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B. Morphology 
The PVN is composed of distinct parvocellular and magnocellular 
divisions (Krieg, 1932). Swanson and Kuypers (1980) have further 
characterized the nucleus into eight distinct subdivisions, three 
magnocellular and five parvocellular. The anterior magnocellular part of 
the PVN is ventromedial to the descending column of the fornix as it 
enters the hypothalamus from the septum. The medial magnocellular 
division is just caudal to the anterior magnocellular level. The largest 
magnocellular division is the posterior magnocellular part. It first 
appears in the ventromedial PVN, just caudal to the medial magnocellular 
division. After dorsolateral expansion it forms a compact cell mass at 
the lateral margin of the nucleus. Hatton et al., (1976) further 
subdivide this group by defining two distinct populations of large cells 
in the medial and lateral halves of the posterior magnocellular region. 
The lateral group contains cells with multiple nucleoli that are larger 
and more uniform in orientation, when compared to the medial group. The 
posterior magnocellular cells number from 1300-2000 on either side of the 
brain (Olivecrona, 1957; Bodian and Maren, 1951; Swanson and Sawchenko, 
1983). 
There are five distinct parts of the parvocellular division. The 
periventricular part, medial to the rest of the PVN, contains small, 
vertically-oriented fusiform cells. The anterior parvocellular group is 
not well-defined but consists of small- to medium-sized cells at the level 
of the anterior and medial magnocellular parts. Extending through the 
caudal half of the nucleus is the medial parvocellular part, which 
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consists of densely packed cells. The dorsal parvocellular part is also 
in the caudal half of the nucleus and consists of horizontally-oriented, 
medium-sized cells in an elliptical group. The lateral parvocellular part 
of the PVN is in the caudal third of the nucleus and is the lateral 
expansion of the parvocellular part (the wings). These cells are 
horizontally-oriented, medium-sized and fusiform shaped. At its maximum 
extent the lateral parvocellular PVN extends laterally over the descending 
column of the fornix, about 750-1000 um from the midline (Swanson and 
Sawchenko, 1983). 
Cells in the parvocellular division project primarily to the 
external lamina of the median eminence (Wiegand and Price, 1980; Swanson 
et al., 1980) and to the brainstem (dorsal vagal complex) and spinal cord 
(Hosoya and Matsushita, 1979; Swanson and Kuypers, 1980). The PVN is also 
known to project to those segments of the thoracic cord thought to contain 
sympathetic preganglionic neurons which innervate the kidney (Swanson and 
Mc Kellar, 1979). Cells in the magnocellular division project primarily 
to the posterior level of the pituitary gland (Sherlock et al., 1975). 
The parvocellular division of the PVN contains about 7000 neurons 
in the following distribution: anterior 1650; dorsal 600; lateral 1300; 
medial 2175; periventricular 1275 (Sawchenko and Swanson, 1981). 
C. Role of the PVN in Behavior 
The PVN plays a major role in the control of feeding. Bilateral 
damage to the PVN results in increased levels of food intake and excesive 
weight gain (Leibowitz et al., 1981). This eating behavior can be 
elicited by hypothalamic injections of norepinephrine and other a-
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noradrenergic agonists (Leibowitz, 1975). In particular, injection of 
the a2-agonist clonidine into the PVN initiates a feeding response in 
satiated rats (Marino et al., 1983). Goldman et al. (1985) observed a 
potent feeding response in satiated animals following injection of 
norepinephrine or clonidine into the PVN. This effect was blocked by the 
a-antagonist phentolamine as well as the a2-antagonists rauwolscine and 
yohimbine. These results suggest that a2 receptors in the PVN play a role 
in mediating feeding behavior. Leibowitz et al. (1984) have demonstrated 
that these a2 noradrenergic receptors fluctuate in density with respect to 
the circadian cycle, exhibiting a unimodal peak at the onset of the dark 
cycle, when feeding normally occurs. This shift in a 2 receptor density may 
be correlated with plasma corticosterone levels, which also peak at the 
onset of the dark cycle (Krieger and Hauser, 1978; Wilkinson et al., 
1979). Norepinephrine-stimulated feeding behavior was prevented by 
adrenalectomy and restored by administration of corticosterone (Leibowitz 
et al., 1984). 
D. Afferent Connections to the PVN 
Descending afferent connections to the PVN include a large input 
from the limbic system structures, especially the lateral septa! nucleus 
and the ventral portion of the subicular cortex, as well as input from 
the amygdala, in particular, the medial nucleus (Silverman et al., 1981; 
Tribollet and Dreifuss, 1981). The PVN receives afferent sensory 
information from the telencephalic limbic system. The bed nucleus of the 
stria terminalis receives a large input from the amygdala (Krettek and 
Price, 1978) and smaller projection from the ventral part of the subiculum 
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(Swanson and Cowan, 1977). The bed nucleus has been shown to project to 
the PVN by autoradiographic studies (Swanson and Cowan, 1979). This 
projection innervates all parts of the parvocellular division and the 
oxytocinergic parts of the magnocellular division (Sawchenko and Swanson, 
1981). Electrophysiological studies have shown that stimulation of the 
amygdala or septum can have inhibitory (and sometimes excitatory) effects 
on the PVN magnocellular neurons (Renaud and Arnauld, 1979; Koizumi and 
Yamashita, 1972; Pittman et al., 1981). 
Anterograde autoradiographic techniques were used to describe brain 
stem afferents to various PVN regions (McKellar and Loewy, 1981). The 
parabrachial nuclei and locus coeruleus project to the posterior, 
periventricular, parvocellular and dorsal divisions. The ventral medulla 
projects to the lateral, medial, posterior, dorsal and parvocellular 
divisions. The Al catecholamine cell group projects to the posterior, 
lateral, medial and dorsal divisions, while the NTS projects to the 
parvocellular and dorsal divisions. The projections from the Al and A2 
(NTS) catecholaminergic cell groups to the PVN have been further 
characterized by an immunofluorescence double-labeling procedure to 
determine which anterogradely labeled fibers and terminals in the PVN also 
displayed immunoreactive dopamine ~-hydroxylase, indicating the presence 
of catecholaminergic neurons (Cunningham and Sawchenko, 1988). (See Role 
of Brain Catecholamines in Corticosterone Secretion) 
Studies using retrogradely-transported horseradish peroxidase 
identified cell bodies of neurons that project to the PVN. Labelled cell 
bodies were found in the mediobasal hypothalamus, the limbic system 
(lateral septum, posterornedial arnygdala and ventral subiculum) and the 
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brain stem, including the dorsal raphe nucleus, locus coeruleus, 
parabrachial nuclei, NTS and lateral reticular nucleus (Tribollet and 
Dreifuss, 1981). 
E. Efferent Projections of the PVN 
Descending autonomic projections of the PVN were investigated using 
the anterograde transport technique of Phaseolus vulgaris leuco-agglutinin 
(Luiten et al., 1985). Two major fiber bundles were described. One 
(fiber bundle 1) leaves the PVN dorsally and runs caudally in a dorsal 
periventricular position to reach the midbrain periaqueductal grey, where 
a number of terminal boutons are observed. This bundle then courses 
laterally to join the lateral lemniscus. Some projections innervate the 
dorsal raphe nucleus, the parabrachial nucleus, locus coeruleus and 
pontine raphe. The second group of fibers (fiber bundle 2) runs medially 
and caudally from the PVN and travels in a position dorsal to the 
transition of the internal capsule and medial forebrain bundle. In the 
midbrain, fiber bundle 2 moves laterally to cover the dorso-lateral pole 
of the substantia nigra, and has some terminations in the ventral aspects 
of the reticular formation. At the level of the pons, fiber bundle 2 
moves ventrally to join the lateral lemniscus (and bundle 1) to reach the 
floor of the brainstem. Posterior to the pons, all descending PVN 
efferents are now in a ventral position adjacent to the pyramidal tracts. 
While in the medulla, some fibers branch off to terminate in the reticular 
and medullary raphe nuclei. Nearly all of the bundle fibers traverse the 
lateral reticular nucleus, nucleus ambiguus, parvocellular reticular 
nucleus and area postrema, with an especially dense amount of varicosities 
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and terminal boutons in the NTS and dorsal motor nucleus of the vagus. 
F. Catecholaminergic Innervation of the Hypothalamic PVN 
There is substantive evidence supporting extensive catecholaminergic 
innervation of the PVN (Carlsson et al., 1962; Lindvall and Bjorklund, 
1974; Hokfelt et al., 1974). Most of the adrenergic and noradrenergic 
innervation to the PVN is provided by (1) the Al and Cl cell groups of the 
ventral medulla, (2) the A2 and C2 cell groups in the medial NTS and (3) 
the A6 cell group, the locus coeruleus of the pontine central gray. The 
locus coeruleus receives major fiber projections from the Al region, and 
projects to the most medial parts of the parvocellular PVN (Swanson et 
al., 1981). 
G. Neuroactive Substances in the PVN 
The colocalization of CRF and vasopressin in the parvocellular PVN 
has already been presented (see CORTICOSTERONE: CRF). These are only two 
of many neuroactive substances found in the PVN by immunohistochemical 
studies. Swanson and Sawchenko (1983) have compiled a thorough listing: 
Cell Bodies include oxytocin and vasopressin in the magnocellular PVN 
(Swaab et al., 1975; Vandesande and Dierickx, 1975); somatostatin in the 
periventricular part of the parvocellular PVN (Dierickx and Vandesande, 
1979); dopamine in the periventricular and adjoining parvocellular PVN 
(Hokfelt et al., 1973); met- and leu-enkephalin in the magnocellular and 
pavocellular PVN (Rossier et al., 1979; Finley et al., 1981); neurotensin 
in the medial and periventricular parts of the parvocellular PVN (Kahn et 
al., 1980); dynorphin coexists with vasopressin in the magnocellular PVN 
(Watson et al., 1982); substance Pin the parvocellular PVN (Ljungdahl et 
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al., 1978); glucagon in the magnocellular PVN (Tager et al., 1980); renin 
in the oxytocinergic parts of the magnocellular PVN (Fuxe et al., 1980); 
and ACTH and i-endorphin in the magnocellular PVN (Joseph and Sternberger, 
1979; 'Watkins, 1980). The PVN is also the major source of atrial 
natriuretic peptide (ANF)-containing cells that project to the median 
eminence (Palkovits et al., 1987). Double-labelling studies with antisera 
to GAD and CRF in the PVN have indicated that a sub-population of CRF-
containing neurons contain the inhibitory neurotransmitter GABA (Meister 
et al., 1987). 
Nerve terminals and fibers in addition to norepinephrine, 
epinephrine and serotonin (previously described) include "cholinoceptive" 
acetylcholine neurons (Kimura et al., 1981); ACTH, i-endorphin and a-MSH 
in the parvocellular and oxytocinergic divisions of the magnocellular PVN, 
all of which originate in the arcuate nucleus (Joseph, 1980; Bloom et al., 
1978; Jacobowitz and O'Donohue, 1978); VIP in the periventricular part of 
the parvocellular PVN (Sims et al., 1980); GABA (Perez de la Mora et al., 
1981); TRH in primarily parvocellular PVN (Hokfelt et al., 1975); and 
sparse fibers of LHRH (Jennes and Stumpf, 1980); bradykinin (Correa et 
al., 1979); prolactin (Fuxe et al., 1977) and angiotensin II (Fuxe et al., 
1976; Changaris et al., 1978). 
a. Neuropeptide Y 
The distribution of neuropeptide Y (NPY) immunoreactivity in the 
PVN as well as its coexpression in noradrenergic and adrenergic brain stem 
groups has been determined with the retrograde transport-double immunohis-
tochemical techniques (Sawchenko et al., 1985). Antisera to phenyl-
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ethanolamine-N-methyltransferase (PNMT) was used as a marker for 
adrenergic neurons, and dopamine-&-hydroxylase (DBH) antisera was used as 
a marker for adrenergic and noradrenergic neurons. The results indicated 
a dense NPY input to most parts of the parvocellular PVN in a similar, yet 
more extensive distribution than that stained by DBH antisera. In the 
magnocellular division, NPY-stained fibers were evenly distributed 
throughout areas containing oxytocinergic and vasopressinergic fibers. 
Catecholaminergic fibers were preferentially associated with vasopres-
sinergic fibers. Combined retrograde transport-double irnrnunohistochemical 
labeling studies demonstrated that NPY irnrnunoreactivity is extensively 
contained within the adrenergic Cl, C2 and C3 cell groups, with somewhat 
less irnrnunoreactivity in the noradrenergic cell groups, mostly limited to 
neurons in the Al cell group. 
Leibowitz et al. (1986) found that NPY injected directly into the 
PVN increased plasma corticosterone levels within 15 minutes of infusion. 
The NPY response was similar to that for epinephrine and norepinephrine 
(See CORTICOSTERONE: Stimulation by Norepinephrine and Epinephrine). 
Also, NPY injected into the third ventricle results in robust feeding 
behavior in satiated rats (Allen et al., 1975) in a similar manner to 
adrenergic neurotransmitters (See PVN: Role in Behavior). Studies by Sahu 
et al. (1988) suggest that NPY neurons in the brainstem project to the PVN 





Male Sprague-Dawley rats (200-250 g) were purchased from Sasco-
King Animal Laboratories (Oregon, WI). The rats were housed, two per 
cage, in a temperature (20-22°C), humidity (50-55%) and illumination (12:12 
hour light/dark cycle; lights on at 0700 h) controlled room. Water and 
food (Wayne Lab Blox, Lab Mills Inc. , Chicago, IL) were available ad 
libitum. 
B. Surgery 
All surgery was performed under pentobarbital anesthesia (50 
mg/kg, i.p.). The rats received atropine sulfate (0.4 mg/kg, i.m.) to 
reduce respiratory tract secretion and ampicillin ( 50 mg/kg, i. m.) to 
prevent infection. Chloramphenicol (1% ophthalmic ointment) was topically 
applied around the wound margin. The rats were euthanized by decapitation 
with a guillotine in an area outside the rat room. Trunk blood was 
collected into centrifuge tubes containing 0.5 ml 0.3 M ethylenediamine 
tetra acetic acid (EDTA; pH 7.4). 
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c. Electrolytic Destruction of the PVN 
Bilateral electrolytic lesions in the PVN were produced by passing 
1. 0 mA (D. C.) current for 10 seconds through an intracranial cathode. The 
anode was clipped to the wound margin. The cathode was a stainless steel 
pin (0.25 mm diameter) insulated with Epoxylite except for 0.5 mm of its 
tip. A Kopf stereotaxic apparatus and a Grass DC constant current lesion 
maker were used. The coordinates for the lesion site were 6.0 mm rostral 
to lambda, 0.5 mm lateral to the midsagittal suture, and 8.3 mm ventral 
to the skull surface, with the incisor bar set at -4. 0 mm. Control 
animals were treated identically except that the electrode was not lowered 
into the skull. The rats were allowed to recuperate from surgery for 14 
days, after which time they were subjected to a conditioned emotional 
(fear) response paradigm (GER). The CER procedure is described in detail 
below. The rats were sacrificed by decapitation immediately following the 
last CER procedure. Trunk blood was collected and assayed as described 
below. The brains were removed and saved for histological verification 
of the lesion placement. Eight rats were included in the sham/control as 
well as the sham/stress group, while 12 rats per group were used in both 
the lesion/control and lesion/stress group. 
D. Electrolytic Destruction of the Nucleus Reuniens 
Bilateral electrolytic lesions of the nucleus reuniens were 
produced by passing 1.0 mA current for 5 seconds through an intracranial 
cathode while the anode was clipped to the wound margin. The coordinates 
for the lesion site were 5.35 mm rostral to lambda, 0.4 mm lateral to the 
midsagittal suture and 8. 0 mm ventral to the skull surface, with the 
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incisor bar set at -4.0 mm. Eight rats were included in the sham/control 
as well as the sham/stress group, 10 rats were used in the lesion/control 
and 12 rats were used in the lesion/stress group. The rest of the 
protocol for this experiment was identical to that described in the 
previous section (Electrolytic Destruction of the PVN). 
E. Microiniections of Ibotenic Acid into the PVN 
Bilateral stereotaxic microinjections of ibotenic acid (Sigma, 
St. Louis, MO) were made using a Kopf stereotaxic apparatus with a 5 µl 
Hamilton syringe and a Trent Wells hydraulic microdrive, to allow for a 
slow delivery rate. Ibotenic acid (10 µg/µl) was dissolved in 0.01 M 
phosphosaline buffer (PBS, pH 7.4), and injected in a volume of 0.3 µl 
per side over five minutes (Fitzsimons and Ciriello, 1986). The injection 
coordinates (incisor bar at -4.0 mm) were 5.7 mm anterior to lambda, 0.5 
mm lateral to the midsagittal suture and 8. 5 mm ventral to the skull 
surface. Control animals received an injection of the vehicle. After 
completion of the injection (five minutes), the needle was left in situ 
for an additional five minutes to prevent dorsal diffusion of the 
neurotoxin along the needle track. The rats were allowed to recuperate 
from surgery for 14 days, after which time they were subjected to the CER 
procedure. The rats were sacrificed by decapitation immediately following 
the CER procedure, and trunk blood was collected and later assayed. Nine 
rats were included in the vehicle/control and eight rats in the vehicle/-
stress group, while 12 rats per group were used in both the ibotenic 
acid/control and ibotenic acid/stress group. 
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F. Microinjections of 6-Hydroxydopamine into the PVN 
Bilateral stereotaxic microinjections of 6-0HDA-HBr (Regis, Morton 
Grove, IL) were made using a Kopf stereotaxic apparatus with a bilateral 
cannula constructed of two 26 gauge stainless steel tubes (injectors) with 
a 1. 0 mm distance between centers. The cannula was connected with 
flexible tubing to two 25 ul Hamilton syringes and a Sage Instruments 
syringe pump, model 355. 6-0HDA was dissolved in 0.1% ascorbic acid in 
physiological saline, to prevent autooxidation. In addition, the vials 
of drug solution were kept on ice and covered with aluminum foil to 
prevent light exposure. 6-0HDA was injected bilaterally over a five 
minute period, in a concentration of 8.0 µg free base in 1.5 µl saline 
containing 0.1% ascorbic acid. Control animals received an injection of 
the vehicle (0.1% ascorbic acid in physiological saline). After completion 
of the injection, the needle was left in situ for an additional five 
minutes to inhibit dorsal diffusion of the neurotoxin along the needle 
track. The rats were injected with the monoamine oxidase inhibitor 
pargyline ( 30 mg/kg, i. p. ; Sigma, St. Louis, MO) 30 minutes prior to 
surgery, to augment the neurotoxic effect of 6-0HDA. The coordinates for 
the injection site were 5.7 mm rostral to lambda, 0.5 mm lateral to the 
midsagittal suture and 8. 7 mm ventral to the skull surface, with the 
incisor bar set at -4.0 mm. The rats were allowed to recuperate from 
surgery for 14 days, after which time they were subjected to the CER 
paradigm, described below. The rats were sacrificed by decapitation 
immediately following the last CER procedure. Trunk blood was collected 
and assayed as described below. The extent of damage to noradrenergic 
nerve terminals was determined by immunocytochemical techniques (see 
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below). Eight rats were included in the vehicle/control as well as the 
vehicle/stress group, while 12 rats per group were used in both the 6-
0HDA/control and 6-0HDA/stress group. 
G. Microinjections of Sotalol into the PVN 
Rats were placed in a Kopf stereotaxic apparatus and implanted with 
chronic bilateral guide cannulae (Plastic Products, Roanoke, VA). The 
guide cannulae were constructed of two 26 gauge stainless steel tubes with 
a 1.0 mm distance between centers. The inner stylets were constructed of 
33 gauge stainless steel wire. The rats were allowed to recuperate from 
surgery for 14 days, and were handled each day following the surgery to 
condition them for handling during the injection. At the end of the 14 
day period, the rats were subjected to the CER procedure, described below. 
In this particular study, the rats were transported in their home cage to 
the CER room, wrapped in a small towel, and held while the dust cap and 
stylets were removed and replaced with a 33 gauge bilateral injector. The 
rats received an injection of either vehicle or sotalol, or no injection 
at all. All injections were performed approximately three minutes before 
placement in the stress chamber, and 13 minutes before sacrifice. The 
volume (0.5 µl per side) was injected over a 60 second interval. The 
injector remained in situ for an additional 60 seconds to help prevent 
dorsal diffusion of the drug. Sotalol was injected bilaterally (0.5 µl 
per side), using two 25 ul Hamilton syringes and a CMA microinjection 
pump. The concentration of sotalol was 2.0 µg in 0.5 µl of physiological 
saline. Vehicle rats received an injection of saline. The non-injected 
rats had their dust caps and stylets removed and injectors placed, but no 
injection occured. The rats were sacrificed by decapitation immediately 
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following the CER procedure. Trunk blood was collected and assayed as 
described below. Fourteen rats were included in the vehicle/control and 
vehicle/stress groups. The non-injected/control and non-injected/stress 
groups had six rats each. Sixteen rats were included in the sotalol/-
control and eighteen rats were in the sotalol/stress group. 
H. Histology 
Lesion placement and drug injection sites were verified histologi-
cally. The brains were preserved in buffered formalin for 48 hours. The 
brains were then infiltrated with sucrose by successive four hour 
intervals in 5% and 10% sucrose solutions, respectively. The brains were 
stored in a 20% sucrose solution until they were cut on a cryostat (40 
micron sections) and stained by the cresyl violet method and inspected by 
a microscope to verify the position of the tip of the needle or extent of 
lesion damage. 
I. Immunocytochemistry 
The brains from the 6-0HDA-treated rats were fixed for five hours 
in a solution containing 4% paraformaldehyde-0.05% glutaraldehyde in 0.10 
M phosphate buffer, pH 7.5 at 4°C. They were then transferred to a 15% 
sucrose PBS solution where they were stored overnight at 4°C (Furness et 
al., 1978). The brains were then mounted in a cryostat, frozen and cut 
into 40 micron sections. These sections were floated in 0.05 M PBS and 
mounted on slides and allowed to air dry. The slides were then placed in 
air-tight slide boxes and kept at 0°C until processed (approximately 48 
hrs). Sections were then washed and incubated in immunocytochemistry 
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(ICC) buffer consisting of phosphosaline buffer (PBS), 1.0% normal goat 
serum (from second antibody host species), 0.1% gelatin, 0.01% thimerosal, 
O - 0.002% neomycin, and 0 - 0.2% triton X-100. Sections were incubated 
consecutively in the primary antibody, rabbit anti-bovine adrenal 
medullary dopamine ~-hydroxylase (DBH, 1:1000 dilution) for 12 hours in 
humidity-controlled chambers at 4°C. The DBH antibody was obtained from 
two sources: (1) Eugene-Tech, Allendale, NJ and (2) Dr. Eric Schweitzer, 
Madison, WI. The two DBH antibodies gave nearly identical results when 
tested on control rats. This incubation was followed by addition of a 
1:50 dilution of goat anti-rabbit IgG followed by an incubation with 1:200 
peroxidase-antiperoxidase (rabbit PAP) solution for 30 minutes at room 
temperature. Sections were washed between each immune incubation with 
0.02 M PBS. Bound peroxidase was visualized by incubating sections in 25 
mg/100 ml diaminobenzidine tetrahydrochloride (DAB-4HC1) and 0.01% 
hydrogen peroxide for 5-7 minutes. To increase sensitivity this solution 
also included 2.5% nickel ammonium sulfate. Sections were washed, mounted 
with cover slips, and viewed on a Leitz Ortholux photomicroscope. 
J. Stress (GER) Procedure 
In each of the experiments, the rats had at least a two-week post-
operative recovery period before being subjected to the conditioned 
emotional response (GER) paradigm. The GER was performed in a ten-inch 
square, clear Plexiglass chamber with a grid floor composed of stainless 
steel rods (0.3 inches in diameter) spaced 0.5 inches apart. The chamber 
was illuminated by a 7.5 W incandescent lamp. The chamber was located 
inside a larger, rectangular sound-attenuating box equipped with a two-
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way mirror (13" x 9") so that the rat's behavior could be observed. The 
sound-proof box also had a small fan in the back wall for ventilation. 
Scrambled current (0.8 mA D.C.) shock for 10 seconds was delivered through 
the grid floor by a Grayson-Stadler shock generator. 
The rats were assigned at random before testing to a particular 
treatment group (control or stress) such that cage mates were members of 
the same group. Cage mates were tested sequentially and at the same time 
each day (between 10:00 and 15:00 hours) on four consecutive days. 
On each day, the rats were transported ten feet from their living 
quarters to the stress chamber. Ten minutes following placement in the 
chamber, the experimental animals received an inescapable foot shock, then 
were returned to their home cage. This procedure was repeated for three 
consecutive days. The behavior of the rats was observed on days 3 and 4 
of the CER paradigm. It was apparent from these observations that the 
stressed rats had learned that their placement in the chamber would be 
followed by a foot shock. By the third day, in contrast to the control 
animals, the stressed rats defecated, urinated and demonstrated freezing 
(no movement) behavior. On the fourth day, after 10 minutes in the test 
chamber, instead of receiving shock the rats were removed, transported to 
a third area outside the stress room and immediately sacrificed by 
decapitation. The control rats were treated identically except that shock 
was not administered at any time. 
The stress chambers were cleaned carefully after each rat had been 
tested. Fecal boli and urine were removed, as well as washing the grid 
floor and sides of the plexiglass chamber. This was to prevent the 
analgesic effect described by Fanselow (1985) that can occur when an 
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unstressed rat is placed in a chamber containing the odor of a rat that 
has received an electric shock. Rats have been shown to release an 
innately recognized odor in response to many types of aversive events 
(Brown, 1979). In particular, aversive electric shock elicits an odor 
that conspecifics can discriminate from the odors of unstressed rats 
(Valenta and Rigby, 1968). These odors have been shown to interfere with 
the acquisition of one-way shock avoidance (Dua and Dobson, 1974). 
K. Biochemical Determinations 
1. Plasma Renin Activity (PRA) 
PRA was measured by radioimmunoassay for generated angiotensin I 
(Haber et al., 1969; Stockigt et al., 1971). The pH of the samples was 
reduced to pH 6.5 by addition of 0.5 ml of 0.5 M phosphate buffer pH 6.0. 
The conversion of angiotensin I to angiotensin II was prevented by 
addition of 0.025 ml of 8-hydroxyquinoline (8-HQ; 10% suspension in 0.3 
M EDTA; 3.4 mM final concentration; Mallinckrodt, St. Louis, MO) and 0.020 
ml of phenylmethylsulfonyl fluoride (PMSF; 5 g in 150 ml ethanol; 2.5 mM 
final concentration; Sigma, St. Louis, MO). Plasma samples were incubated 
for three hours at 37°C to generate angiotensin I (AI). The incubation was 
stopped by immersion of the samples in boiling water for three minutes. 
The radioimmunoassay of AI was performed with an antiserum against AI at 
a dilution of 1:30,000, and a total binding of 35%. The antibody was 
added to the samples in a volume of 0.3 ml (AI antiserum in a 0.1 M Tris 
buffer, pH 8.0, containing 0.1% gelatin) and incubated overnight at 4°c. 
The tracer ( 125I labelled AI) was added to the samples the following 
morning, in a volume of 0.4 ml per tube, approximately 10,000 counts per 
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minute per tube. On the next day, the antibody-bound (iodinated AI) 
tracer was separated from the free tracer by addition of O. 5 ml of a 
suspension containing activated charcoal and dextran T500 (Pharmacia, 
Piscataway, NJ) and centrifugation at 2000 x g for 15 minutes. The pellet 
containing the unbound tracer was counted on a micromedic 4/200 plus 
automatic gamma counter which was connected via a buffer (Quadram 
microfazer) to an IBM PC-AT computer. The data were analyzed by a program 
(RIA-AID) that was purchased from Robert Maciel Associates (Arlington, 
MA). The sensitivity limit of the RIA is 10 pg AI per tube and the intra-
assay variability was 4.0%. The inter-assay variability was 7.4% (Van de 
Kar et al., 1984). The tracer (AI; Beckman, Arlington Heights, IL) was 
iodinated via the chloramine T (Sigma, St. Louis, MO) method (Greenwood 
et al., 1963). Phosphate buffer (0.05 M; 0.02 ml), 12 µl AI (0.5 µg/µl) 
and 20 µl chloramine T (3.5 mg/ml phosphate buffer) were added to the vial 
containing the 125I and mixed for three seconds. This was immediately 
followed by addition of 25 µl of sodium metabisulfite (4. 5 mg/ml phosphate 
buffer; J. T. Baker Chemical Co. , Phillipsburg, NJ) to terminate the 
reaction. Chromatography of the iodinated AI was performed first by ion 
exchange (Biorad AG-1X4, 200-400 mesh) chromatography. The column 
consisted of a siliconized Pasteur pipette (5 3/4"; Scientific Products) 
with a small amount of glass wool placed in the tip of the pipette to 
support the anion exchange res in. Fractions (12 drops per tube) were 
collected from the column and the radioactivity in each tube was measured. 
The radioactive peak fractions eluted off this column were then placed on 
a Sephadex G-15 column for gel filtration and eluted with 0.05 N acetic 
acid containing 0.1% bovine serum albumin (Sigma, St. Louis, MO). Two ml 
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fractions were collected off the Sephadex column and measured for 
radioactivity. The tubes containing the radioactive AI were pooled and 
stored at -10°c. 
2. Plasma Renin Concentration (PRC) 
Renin is the enzyme responsible for the conversion of the 
substrate angiotensinogen, produced by the liver, to 
Angiotensin I. The measurement of plasma renin activity reflects the 
concentration of renin as well as renin substrate (angiotensinogen) in 
plasma. The normal angiotensinogen concentration is only about or less 
than Km (Reid et al., 1978) and thus much less than the concentration 
required to generate AI at maximum velocity (Vmax). Studies by Van de 
Kar et al. (1981) have demonstrated that 5-HT dependent changes in plasma 
renin activity are not accompanied by changes in plasma angiotensinogen 
levels. However, since electrolytic lesions in the PVN could cause a 
reduction in corticosterone levels, this could lead to decreased secretion 
of angiotensinogen from the liver. This would cause plasma renin activity 
values to be low even when renin levels were unaffected. The assay for 
plasma renin concentration involves the addition of a saturating 
concentration of exogenous renin substrate to the samples such that renin 
is working at Vmax. The measurement of plasma renin concentration 
eliminates the possibility that decreased substrate levels would be 
misinterpreted as decreased levels of renin. 
The renin substrate was plasma from nephrectomized rats which 
received dexamethasone (0.2 mg/rat) 24 hours before sacrifice. The plasma 
samples (0.2 ml) received 0.1 ml of nephrectomized plasma, 0.1 ml of 0.5 
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M phosphate buffer pH 6.0, and 5 µl each of PMSF and 8-hydroxyquinoline 
(to a final concentration of 2.5 mM and 3.4 mM, respectively). The 
mixture was incubated at 37°C for one hour. The reaction was stopped by 
immersion of the tubes in a boiling water bath for three minutes. The 
radioimmunoassay of AI is as described for PRA. 
3. Plasma Angiotensinogen 
This radioimmunoassay is similar to that for PRC except that a 
saturating amount of the enzyme renin (from kidney homogenates) is added 
to the plasma samples before incubation to allow conversion of endogenous 
renin substrate to AI (Menard and Catt, 1972). Therefore any differences 
in the production of AI will be attributed to differences in substrate, 
not enzyme levels. 
The plasma samples (0.1 ml) received 0.1 ml of 0.5 M phosphate 
buffer pH 6.0, 0.1 ml renin (from rat kidneys homogenized in cold water 
1 g/ml at a 1:1,000 dilution), and 5 µl each of PMSF and 8-HQ. The 
mixture was incubated at 37°C for one hour. The reaction was stopped by 
immersion of the tubes in a boiling water bath for three minutes. The 
remainder of the radioimmunoassay for AI is as described for PRA. 
4. Plasma Corticosterone 
Corticosterone radioimmunoassays on unextracted plasma (5 and 10 
µl) were performed using procedures and antiserum from Radioassay Systems 
Laboratories (Carson, CA). The binding proteins were denatured by 
incubation of the sample tubes and assay buffer in a hot water (80°C) bath 
for twenty minutes. The standards were made of serial dilutions of 
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corticosterone (Steraloids, Wilton, NH) in assay buffer. The antiserum 
(catalog # 1472, lot # 3R3-38) was used at a final dilution of 1:10,500 
and total binding of 40%. The incubation of the samples (or standard) 
with the antiserum and tracer (corticosterone l,2,6,7- 3H(N)-; NET-399, 
New England Nuclear) occurred overnight at 4°C. The antibody-bound tracer 
was separated from the unbound tracer by addition of a charcoal-Dextran 
T70 suspension, centrifugation, and decanting of the supernatant into 
scintillation vials containing 5 ml of a scintillation cocktail (4 g of 
Omnifluor in 1 liter of toluene). The samples containing the supernatant 
and scintillation cocktail were counted in a Packard liquid scintillation 
counter. The data were stored on a diskette by a Diskstore (United 
Technologies, Packard) and were analyzed using the RIA-AID software 
(Robert Maciel Associates, Arlington, MA). The intra- and inter-assay 
variability were 4.5% and 11.9% respectively (Van de Kar et al., 1985). 
L. Statistics 
The data are reported as mean ± S. E .M. (standard error of the 
mean). The sample mean was the average of the number of animals in each 
group (n). The standard error of the mean was calculated as described 
below. Statistical analyses of the data was performed by a two-way 
analysis of variance (ANOVA). Individual group means were compared by 
Student Newman-Keul's multiple range test (Steel and Torrie, 1960). 
The most common measurement of central tendency for given samples 
of a population is the arithmetic average or mean. In addition to the 
measure of central tendency, it is important to be aware of how the 
samples differ in variability. This measure is the variance, or its 
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square root, the standard deviation (S.D.). This variance will provide 
information as to whether an observation is an ordinary or an unusual 
value in a specified population, giving a small value when the observa-
tions cluster closely about a central value, and a larger value when they 
are spaced widely. The sum of squares is the sum of the squared 
deviations from the arithmetic mean. The quantity (n-1) is known as 
degrees of freedom. Sum of squares is divided by degrees of freedom to 
give unbiased estimates of the population variances. Since sample means 
are also subject to variation, the standard error of the mean is also 
reported. It is calculated by dividing the S.D. by the square root of the 
number of observations in the mean. 
1. Analysis of Variance (ANOVA) 
Analysis of variance is defined by Steel and Torrie (1960) as 
" ... an arithmetic process for partitioning a total sum of squares into 
components associated with recognized sources of variation." Using this 
type of test, the data are classified according to their treatment group. 
With respect to the present studies, a two-way analysis of variance was 
the appropriate test, since the animals were subjected to two separate 
treatments: (1) surgical (or drug) and (2) behavioral (stress). 
The error mean square is an average of the components contributed 
by the treatments. It is an estimate of a common variation among 
observations of the same treatment group. Treatment mean square is an 
independent estimate of the variance when the null hypothessis is true. 
F is defined as the ratio of two independent estimates of the same 
variance, thus, the F value is obtained by dividing the treatment mean 
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square by the error mean square. Once F has been calculated, it is 
compared with the tabular F at the appropriate degrees of freedom at the 
.05 (5%) probability level. If the calculated F is greater than the 
tabulated F, then the null hypothesis (no difference between population 
means) can be rejected and it can be concluded that there are real 
differences among treatment means. With respect to the two-way ANOVAS of 
the present studies, three F values were obtained: Fa for the surgical or 
drug treatment, Fb for the stress treatment, and Fa x b for the interaction 
between the drug and stress treatments. The F value reported was the one 
that accounts for interaction between both the stress and surgical/drug 
treatment groups. 
2. Student-Newman-Keuls' Test 
Multiple comparison tests can be used to compare each treatment 
mean with every other treatment mean. Student-Newman-Keuls' test is a 
multiple range test " ... for judging the significance of a set of 
differences; it permits decisions as to which differences are significant 
and which are not ... Error rate is seen to apply neither on an experiment-
wise nor a per-comparison basis since a particular range test may be made 
for one or more comparisons in a particular experiment" (Steel and Torrie, 
1960). This test also takes into account the number of treatments in the 
experiment. To perform the Newman-Keuls' test, the mean square error from 
the ANOVA is divided by the harmonic mean (average number of n per group). 
The square root of this number is Sx, the standard error of the mean. Next 
a tabular value, q, is selected. This value is based on a .05 level of 
probability, and the appropriate p (number of treatment means) and degrees 
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of freedom. Q is multiplied by Sx to give a range of significance. If the 
distance between two means is greater than the range of significance, then 




A. Electrolytic Lesions in the PVN 
Figure 1 is a coronal section of an intact PVN, stained with cresyl 
violet. Figure 2 shows an electrolytic lesion in the PVN. These lesions 
did not extend caudally beyond the PVN, and the dorsomedial nucleus was 
intact. There was some damage to the caudal aspect of the anterior 
hypothalamic area, as in Figure 2. This was not evident in all cases. 
The lesions did not extend laterally to the fornix. Only lesions which 
destroyed 90% or more of the PVN and did not extend dorsally into the 
thalamus were considered in the statistical evaluation of hormonal data. 
Following histological verification, the lesion control/group consisted 
of five rats, while the lesion/stress group consisted of seven rats with 
accurate and complete PVN lesions. One rat did not survive the anesthesia 
in the sham/control group, making the total for this group seven rats. 
Electrolytic lesions in the PVN prevented the stress-induced 
increases in plasma renin activity (PRA) (Figure 3), plasma renin 
concentration (PRC) (Figure 4), and in plasma corticosterone levels 
(Figure 5). By comparison, rats with lesions which missed the PVN (n=S), 
but destroyed areas rostral to the PVN, showed no inhibition of the effect 
of stress on PRA (24.0 ± 3.2), PRC (33.7 ± 6.2) and corticosterone (29.3 
± 6.1) levels. 
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FIGURE 1 
CORONAL SECTION OF RAT 
BRAIN WITH AN INTACT 
PARAVENTRICULAR NUCLEUS 
FIGURE 2 
CORONAL SECTION OF RAT BRAIN 
WITH AN ELECTROLYTIC LESION 

























The effect of stress on plasma renin activity in rats with electrolytic 
PVN lesions. The data represent mean± S.E.M., n=7 for the sham/control 
group, n=6 for the sham/stress group, n=5 for the lesion/control group, 
and n=7 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 5.7 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the lesion F(l, 21) -
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LESION PVN LESION 
The effect of stress on plasma renin concentration in rats with electro-
lytic PVN lesions. The data represent mean± S.E.M., n=7 for the 
sham/control group, n=6 for the sham/stress group, n=5 for the lesion/-
control group, and n=7 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 4.5 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a highly significant effect of the lesion F(l,21) 








0 """' 20 u 1J 
- "' f--- Ol ()'.'. ::t 















The effect of stress on plasma corticosterone levels in rats with 
electrolytic PVN lesions. The data represent mean± S.E.M., n=7 for the 
sham/control group, n=6 for the sham/stress group, n=5 for the lesion/-
control group, and n=7 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 7.0 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,21) = 11.06; 
and lesion*stress interaction F(l, 21) = 14. 245. The lesion did not 
produce a significant effect F(l,21) = 0.64. 
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B. Electrolyic Lesions in the Nucleus Reuniens 
In a control experiment, lesions in the thalamic nucleus reuniens 
were made, dorsal and caudal to the PVN. These lesions were small, 
discrete and did not extend to the region of the third ventricle.and the 
PVN (Figure 6). Following histological verification of placement in the 
nucleus reuniens, five rats were included in the lesion/control and six 
rats included in the lesion/stress group. There were six rats in the 
sham/stress group, and eight rats in the sham/control group. 
Electrolytic lesions in the nucleus reuniens did not prevent the 
stress-induced increase in plasma renin activity (Figure 7) or plasma 
renin concentration (Figure 8). The stress-induced increase in plasma 
corticosterone levels was attenuated but not completely blocked by nucleus 
reuniens lesions (Figure 9). It is possible that this lesion interrupted 
afferent fibers to the PVN that are involved in stimulating CRF neurons 
in the PVN. Stressed rats in which the lesions missed both the nucleus 
reuniens and the PVN (n=S), had hormonal values similar to the sham/stress 
group and the group in which the nucleus reuniens was destroyed (PRA 14.3 
± 3.6; PRC 13.5 ± 1.8; and corticosterone 18.2 ± 1.7). 
FIGURE 6 
CORONAL SECTION OF RAT BRAIN WITH AN 
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The effect of stress on plasma renin activity in rats with electrolytic 
lesions in the nucleus reuniens. The data represent mean± S.E.M., n-8 
for the sham/control group, n=6 for the sham/stress group, n=5 for the 
lesion/control group and n=6 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 6.4 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,21) = 11.58; 
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The effect of stress on plasma renin concentration in rats with electro-
lytic lesions in the nucleus reuniens. The data represent mean± S.E.M., 
n=8 for the sham/control group, n=6 for the sham/stress group, n=S for the 
lesion/control group and n=6 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 7.4 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,21) = 10.291; 
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The effect of stress on plasma corticosterone levels in rats with 
electrolytic lesions in the nucleus reuniens. The data represent mean± 
S.E.M., n=7 for the sham/control group, n=6 for the sham/stress group, 
n=5 for the lesion/control group and n=6 for the lesion/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 6.5 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,20) - 10.29; 
but not of the lesion F(l,20) = 0.601 or lesion*stress interaction F(l,20) 
= 1. 83. 
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c. Injection of Ibotenic Acid into the PVN 
Figure 10 is a section of an intact PVN stained with cresyl violet. 
Figure 11 shows the needle tracks and destruction of neurons in the PVN 
following an injection of ibotenic acid. Acceptable lesions were 
restricted to the PVN and, compared with control sections, showed greater 
than 50% cell loss. Following histological verification of the injection 
site and evaluation of the hormonal data, there were seven rats included 
in both the vehicle/control and vehicle/stress group. Four rats in the 
ibotenic acid/control and six rats in the ibotenic acid/stress group were 
considered accurate PVN lesions. 
Ibotenic acid-induced lesions in the PVN prevented the stress-
induced increase in plasma renin activity (Figure 12) and plasma renin 
concentration (Figure 13). Stress-induced increases in corticosterone 
levels also were prevented by ibotenic acid lesions of neurons in the PVN 
(Figure 14). By comparison, stressed rats with ibotenic acid injections 
which missed or caused unnoticeable damage to neurons in the PVN (n=6) had 
PRA (28.9 ± 3.8), PRC (35.5 ± 4.5) and corticosterone levels (16.9 ± 1.9) 
which were indistinguishable from the vehicle/stress group. Thus far, the 
data suggested that cell bodies in the PVN are involved in stress-induced 
renin and corticosterone secretion. 
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FIGURE 10 
INTACT PARAVENTRICULAR NUCLEUS 
PARAVENTRICULAR NUCLEUS FOLLOWING 
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The effect of stress on plasma renin activity in rats with ibotenic acid 
lesions in the PVN. The data represent mean ± S. E .M., n=7 for both 
vehicle groups, n=4 for the ibotenic acid/control group, and n=6 for the 
ibotenic acid/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 10.5 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the drug F(l,20) = 4.959; 
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The effect of stress on plasma renin concentration in rats with ibotenic 
acid lesions in the PVN. The data represent mean± S.E.M., n=7 for both 
vehicle/control and vehicle/stress groups, n=4 for the ibotenic acid/-
control group, and n=6 for the ibotenic acid/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 13.5 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the drug F(l,20) = 5.063; 
and stress F(l,20) = 8.069. The drug*stress interaction F(l,20) - 3.619 
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The effect of stress on plasma corticosterone levels in rats with ibotenic 
acid lesions in the PVN. The data represent mean± S.E.M., n=7 for both 
vehicle/control and vehicle/stress, n=4 for the ibotenic acid/control 
group, and n=6 for the ibotenic acid/stress group. 
* Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 4.3 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 12.273; 
and stress F(l, 21) 19. 645. The drug*stress interaction was not 
significant F(l,21) = 3.198. 
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o. Injection of 6-0HDA into the PVN 
Figure 15A shows a coronal section of the PVN following vehicle 
injection and staining with dopamine ~-hydroxylase (DBH) antiserum. 
Figure 15B shows a coronal section of the PVN following 6-0HDA injection 
and staining with DBH antiserum, showing loss of DBH immunoreactivity. 
In general, there was a 60-80% reduction in DBH staining (as compared to 
vehicle rats) in a 500-1000 micron area that encompassed the PVN and 
anterior hypothalamus, but did not spread as far as the mediobasal 
hypothalamus. Following immunocytochemical and histological verification, 
the vehicle/control and 6-0HDA/control groups consisted of seven rats 
each, the vehicle/stress group consisted of six rats, and the 6-0H-
DA/stress group had five rats. 
The stress (GER) procedure produced a significant increase in plasma 
renin acivity and concentration as well as increasing plasma corticos-
terone levels in rats which received an injection of vehicle or non-
injected animals. Injection of 6-0HDA into the PVN prevented the effect 
of stress on plasma renin activity (Figure 16) and plasma renin concentra-
ti on (Figure 17) . In addition the effect of stress on plasma cor-
ticosterone levels was also blocked (Figure 18). Since 6-0HDA injections 
into the PVN prevented the stress - induced increase in corticosterone 
levels, it is possible that this caused decreased secretion of the renin 
substrate (angiotensinogen) from the liver. This would cause PRA values 
to be low even though renin levels were unaffected. To test this, in 
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addition to measurements of PRC, plasma angiotensinogen levels were 
determined (Figure 19). There were no differences observed between the 
groups. This suggested that neither stress nor 6-0HDA injections affected 
plasma levels of renin substrate. Thus far the data suggest that 
catecholaminergic neurons or nerve terminals in the PVN play a role in the 
stress-induced increase in renin and corticosterone secretion. 
FIGURE lSA 
CORONAL SECTION FROM RAT INJECTED WITH 
VEHICLE AND STAINED WITH DBH ANTISERUM 
CORONAL SECTION FROM RAT INJECTED WITH 
6-0HDA AND STAINED WITH DBH ANTISERUM, 
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The effect of stress on plasma renin activity in rats with 6-0HDA lesions. 
The data represent mean ± S.E.M.; n=7 for vehicle/control, n=6 for 
vehicle/stress, n=7 for 6-0HDA/control and n=5 for 6-0HDA/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 5.48 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 13.576; 
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The effect of stress on plasma renin concentration in rats with 6-0HDA 
lesions. The data represent mean± S.E.M.; n=7 for vehicle/control, n-6 
for vehicle/stress, n=7 for 6-0HDA/control and n-5 for 6-0HDA/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 12.9 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of the drug F(l,21) = 6.939; 
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The effect of stress on plasma corticosterone levels in rats with 6-0HDA 
lesions. The data represent mean± S.E.M.; n-7 for vehicle/control, n-6 
for vehicle/stress, n=7 for 6-0HDA/control and n-5 for 6-0HDA/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 10.0 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,21) = 9.422. 
There were no significant effects of either the drug F(l,21) = 0.194 or 
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The effect of stress on plasma angiotensinogen levels in rats with 
6-0HDA lesions. The data represent mean± S.E.M.; n-7 for vehicle/-
control, n=6 for vehicle/stress, n=7 for 6-0HDA/control and 
n=5 for 6-0HDA/stress. 
No significant differences found among the groups, p < 0.05. A minimal 
difference of 33.l would be required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates no significant effects of the drug F(l, 21) -
1. 395; stress F(l, 21) = 0. 072; and drug*stress interaction F(l, 21) -
0. 721. 
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E. Injection of Sotalol into the PVN 
Figure 20 shows a coronal section of the PVN stained with cresyl 
violet following a bilateral injection of sotalol into the PVN. Only rats 
in which the tip of the cannula was immediately dorsal to the border of 
the PVN, or inside the dorsal PVN, were acceptable. In several rats, the 
cannulae ended inside the PVN, producing large mechanical lesions. These 
rats were excluded from the statistical analysis of the hormonal data. 
Following histological verification of the injection site, eight rats were 
used in the vehicle/control, five rats in vehicle/stress and non-
injected/stress, and four rats in the non-injected/control group. There 
were six rats used in the sotalol/control group and eight rats in the 
sotalol/stress group. 
Figures 21 and 22 show the effect of stress on plasma renin activity 
and plasma renin concentration, respectively, in rats injected with either 
vehicle or sotalol, or in non-injected rats. Stress-induced increases in 
PRA and PRC were not prevented by injection of sotalol. However, the 
stress-induced increase in corticosterone levels was prevented by 
injections of sotalol into the PVN (Figure 23). 
FIGURE 20 
CORONAL SECTION OF THE PARAVENTRICULAR NUCLEUS 






























The effect of stress on plasma renin activity in rats injected with either 
vehicle or sotalol, or in non-injected rats. The data represent mean± 
S.E.M.; n=8 for vehicle/control, n=4 for vehicle/stress, n=6 for 
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and 
n=5 for non-injected/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 8.42 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,28) - 32.526; 
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The effect of stress on plasma renin concentration in rats injected with 
either vehicle or sotalol, or in non-injected rats. The data represent 
mean± S.E.M.; n=8 for vehicle/control, n=4 for vehicle/stress, n=6 for 
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and 
n=5 for non-injected/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 9.6 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,28) - 17.357; 



























The effect of stress on plasma corticosterone levels in rats injected with 
either vehicle or sotalol, or in non-injected rats. The data represent 
mean± S.E.M.; n=8 for vehicle/control, n=4 for vehicle/stress, n-6 for 
sotalol/control, n=7 for sotalol/stress, n=4 for non-injected/control and 
n=S for non-injected/stress. 
*Significant difference from the corresponding control group, p < 0.05. 
A minimal difference of 8.6 is required between the means by the Student-
Newman-Keuls' test. 
Two-way ANOVA indicates a significant effect of stress F(l,28) = 9.823. 
No significant effect is seen with the drug F(2,28) - 1.724 or drug*stress 
interaction F(2,28) = 1.411. 
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F. Comparison of Normal Plasma Pools to Experimental Controls 
Pooled plasma samples for "normal" and "high" PRA or "normal" and 
"high" corticosterone levels are run routinely with each respective assay. 
The pooled plasma samples are compiled from rat plasma that has been 
previously assayed and classified within the range of "normal" or "high" 
based on its corticosterone or PRA value. A random sample of these 
values, taken from assays run between 1986 and 1989, gave the following 
values (mean± standard error of the mean): 
"normal" PRA 7.6 ± 0.5 (n 23) 
"high" PRA 23.6 ± 2.8 (n 23) 
"normal" corticosterone 8.9 ± 1.1 (n 13) 
"high" corticosterone 20.9 ± 2.0 (n 10) 
The pooled values for "normal" PRA and corticosterone are very 
similar to previously published values for PRA and corticosterone in 
untested control animals, shown below. 
PRA 
Corticosterone 
Untested Control Rats 
7.1 ± 1.2 
8.9 ± 2.1 
(Van de Kar et al., 1985) 
(Van de Kar et al., 1985) 
The normal plasma pool values were compared to the means of the 
sham- or vehicle-treated groups in each of the experiments of this 
dissertation. ANOVA and Newman-Keuls' Multiple Range Test were run to 
determine if significant differences between the groups exist. With 










Comparison of Mean Values: 
Normal PRA Pool versus Experimental 
Sham- or Vehicle-Treated Groups 
Description Mean + Std.Error 
6-0HDA Expt. Vehicle/Control 3.6 ± 0.8 
Electrolytic PVN Sham/Control 4.5 ± 0.6 
Sotalol Expt. Vehicle/Control 6.3 ± 0.5 
+ Non-injected/Control 
Electrolyt. N. Reun. Sham/Cont. 6.4 ± 0.4 
Normal PRA Pool 7.6 ± 0.5 
Ibotenic Expt. Vehicle/Control 9.2 ± 0.9 











Newman-Keuls' Multiple Range Test for PRA 
Treatment vs. Treatment Difference Sig .OS 
Group 4 Group 1 0.94 
Group 4 Group 5 2. 71 
* 
Group 4 Group 2 2.82 
* 
Group 4 Group 6 4.06 
* 
Group 4 Group 3 5.62 
* 
Group 1 Group 5 1. 77 
Group 1 Group 2 1. 88 
Group 1 Group 6 3.11 
* 
Group 1 Group 3 4.68 
* 
Group 5 Group 2 0.11 
Group 5 Group 6 1. 34 
Group 5 Group 3 2.91 
* 
Group 2 Group 6 1. 23 
Group 2 Group 3 2.80 
* 
Group 6 Group 3 1.56 
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The means of the experimental vehicle- or sham-treated goups were 
not significantly elevated above the normal PRA plasma pool. However, 
two experimental groups had PRA values lower than the normal PRA pool 
levels. 









Comparison of Mean Values: 
Normal Corticosterone Pool versus Experimental 
Sham- or Vehicle-Treated Groups 
Description Mean + Std.Error 
Ibotenic Expt. Vehicle /Control 6.5 ± 0.5 
6-0HDA Expt. Vehicle/Control 7.1 ± 0.5 
Normal Corts Pool 8.9 ± 1.1 
Electrolyt. PVN Sham/Control 9.3 ± 2.3 
Electrolyt. N. Reun. Sham/Cont. 12.8 ± 0.9 
Sotalol Expt. Vehicle/Control 12.9 ± 1.2 
+ Non-injected Control 










Newrnan-Keuls' Multiple Range Test for Corticosterone 
Treatment vs. Treatment Difference Sig .05 
Group 3 Group 4 0.49 
Group 3 Group 6 2.36 
Group 3 Group 1 2.75 
Group 3 Group 2 6.31 
* 
Group 3 Group 5 6.34 
* 
Group 4 Group 6 1. 86 
Group 4 Group 1 2.26 
Group 4 Group 2 5.81 
* 
Group 4 Group 5 5.85 
* 
Group 6 Group 1 0.39 
Group 6 Group 2 3.95 
Group 6 Group 5 3.98 
Group 1 Group 2 3.55 
Group 1 Group 5 3.58 
Group 2 Group 5 0.03 
None of the vehicle- or sham-treated experimental groups were 




The following conclusions can be drawn from the results presented: 
(1) Neurons in the PVN mediate the stress-induced increase in renin and 
corticosterone secretion. (2) Catecholaminergic nerve terminals in the 
PVN mediate the effect of stress on renin and corticosterone secretion. 
(3) Stress-induced corticosterone secretion appears to be mediated by ~ 
receptors in the PVN, while (4) stress-induced renin secretion is mediated 
by a receptor that is not ~-adrenergic. Stress-induced renin secretion 
may be mediated by a different catecholamine receptor, a neuropeptide or 
other substance(s) colocalized in catecholaminergic nerve terminals. 
B. Justification of the Stress Paradigm 
Abundant evidence was presented in the literature review to 
demonstrate that renin and corticosterone secretion can be elevated by 
many different stressors. The stress paradigm used in these experiments 
was a conditioned fear paradigm that involved exposing the rats to an 
initially neutral stimulus (the stress chamber) which was followed after 
ten minutes by an aversive stimulus (footshock). The latter unconditioned 
stimulus elicited a range of unconditioned responses, including neuroen-
docrine (increased renin and corticosterone levels) and behavioral 
(defecation, urination, freezing) responses. As the pairings of stimuli 
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were continued, the originally neutral stimulus became a conditioned 
stimulus, capable of eliciting the same responses as the unconditioned 
stimulus. 
1. Classical Conditioning of Fear Stimuli 
Classical conditioning can account for the wide range of stimuli 
that can produce fear in animals and humans (Watson, 1924). An experiment 
by Hunt and Otis (1953) demonstrated that one symptom of fear, defecation, 
can be classically conditioned. They presented a rat with a flashing 
light for three minutes, at the end of which time the animal received an 
electric foot shock. Eight conditioning trials were run. At first, 
defecation occurred primarily when the shock was delivered, but it 
increasingly began to occur during the presentation of the flashing light. 
A similar phenomenon was observed with the conditioned fear 
paradigm used in the experiments of this dissertation. Behavioral 
observations were made throughout the testing procedure, and recorded on 
the third and fourth (final) days. Rats were monitored for defecation 
and urination, as well as exploratory, freezing or grooming behaviors. 
On the first day, the rats were placed in the stress chamber for a ten 
minute interval, at the end of which time they received a mild foot shock. 
The rats were tested in this manner for four consecutive days, the only 
exception being that on the final day, no foot shock was given. On the 
first day in the stress chamber the rats did not defecate until the time 
of the foot shock. However by the third day (and in some cases the 
second), as soon as the rats were placed in the stress chamber they began 
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to defecate. The defecation suggested that the rats had paired the 
placement in the chamber with the impending foot shock, supporting the 
hypothesis that classical conditioning is an integral part of the ability 
of previously neutral stimuli to elicit fear. Lorens et al. (1989) 
reported the number of fecal boli as a defecation score, a quantitative 
measurement of a behavioral response to conditioned fear. 
In the experiments of this dissertation, the control animals 
explored the test chamber and groomed themselves. The stressed animals, 
after the first or second day of conditioning, would sometimes explore, 
and sometimes groom, but for the most part would defecate, urinate and 
exhibit freezing behavior. Freezing behavior consists of tense and silent 
immobility, and is seen in many species in times of danger. The 
observation of freezing behavior in response to the CS represents another 
similarity between my experiments and those presented by Hunt and Otis 
(1953). Normally a rat responds to an electric foot shock with a great 
increase in activity - running around frantically, jumping, and trying to 
escape the shock. However, in my experiments and the experiments of Hunt 
and Otis (1953), the stimulus followed by shock caused a radically 
different behavior - immobility. This is quite an exception to the usual 
pattern of the CS (in my case, the stress chamber) eliciting a similar 
(though not exact) reaction to that of the UCS (the footshock). Gray 
(1971) suggested the possibility that freezing and more active forms of 
escape and avoidance behavior are controlled by separate brain systems, 
and represent a combination of learning and innate behavior. 
The process of producing electrolytic lesions or injecting 
neurotoxins is an invasive procedure that could, theoretically, interrupt 
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fiber pathways that are involved in the learning/conditioning process. 
Because this surgical intervention occurs two weeks prior to the 
behavioral conditioning paradigm, it is important to look for potential 
differences in the behavior of sham or vehicle-injected rats compared with 
rats with electrolytic or chemical lesions in the PVN. Behavioral 
observations during the conditioning process indicated that the lesions 
did not prevent defecation, urination and freezing in the stressed rats. 
This suggests that the lesions did not interfere with the conditioning 
process. 
C. Electrolytic and Ibotenic Acid Lesions in the PVN 
The data suggest that neurons in the PVN mediate the effect of 
stress on renin secretion and confirm results by others (Rivier and Vale, 
1983; Dohanics et al., 1986) that neurons in the PVN mediate the effect 
of stress on corticosterone secretion. This conclusion is based on the 
finding that both complete electrolytic lesions in the PVN and selective 
destruction of cells in the PVN prevented the stress-induced elevation in 
plasma renin activity, plasma renin concentration and plasma cort-
icosterone levels, whereas electrolytic lesions in the thalamic nucleus 
reuniens were ineffective. Ibotenic acid was selected for its ability to 
selectively destroy cell bodies while leaving fibers of passage intact 
(Markowska et al., 1985; Winn et al., 1984). Magnocellular neurons in the 
PVN have been reported to be resistant to the neurotoxic effects of kainic 
acid (Zhang and Ciriello, 1985). Herman and Wiegand (1986) have reported 
that ibotenic acid selectively destroyed parvocellular neurons in a dose-
dependent manner while sparing magnocellular neurons. They reported that 
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loss of parvocellular neurons occurred at 0.5, 0.75, 1.0 and 2.0 µg doses 
of ibotenic acid. Loss of magnocellular neurons (mostly vasopressinergic) 
was observed only after the 2 .0 µg dose. Their protocol involved 
unilateral injections (compared to our protocol of bilateral injections) 
directed towards the central portion of the PVN at the level of the 
posterior magnocellular division. In our study, the drug volume was 
higher (0.3 µl compared to 0.1 µl) and the injection site had to be at 
least 0.5 mm lateral to the midsagittal suture. Injections of ibotenic 
acid closer to the midline led to diffusion of the drug into the third 
ventricle, resulting in death of the rats. We did not observe selective 
sparing of the magnocellular neurons after injections of ibotenic acid. 
The effect of stress on corticosterone secretion is most likely 
propagated by stimulation of CRF neurons in the PVN. The majority of the 
diencephalic CRF-neurons are located in the parvocellular neurons in the 
dorsal and medial subnuclei of the PVN (Liposits et al., 1987; Liposits 
and Paull, 1985). A small number of CRF-neurons also are present in the 
magnocellular divisions of the nucleus (Swanson and Sawchenko, 1983; 
Piekut and Joseph, 1986). Dohanics et al. (1986) reported that the full 
corticosterone and ACTH response to ether or ether plus laparotomy stress 
requires not only an intact PVN, but also an intact neurointermediate 
lobe. Therefore, our data are consistent with the hypothesis that CRF 
neurons in the parvocellular PVN are activated during the CER procedure 
to stimulate ACTH and thus corticosterone secretion. Furthermore, the 
data with corticosterone support the histological verification of the 
accuracy of the lesions in the PVN. The finding that basal corticosterone 
concentration was not altered by the PVN lesions is in agreement with 
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previous studies by Meyerhoff et al. (1987) and Makara et al. (1986), who 
reasoned that in the absence of CRF input, the cells in the pituitary can 
maintain a basal level of ACTH but cannot respond to stimuli which would 
increase ACTH secretion. Similar findings were also reported using CRF 
antisera (Nakani et al., 1985; Ono et al., 1985; Rivier et al., 1982). 
Nucleus reuniens lesions inhibited the effect of stress on 
corticosterone but not renin secretion. This suggests that fibers which 
course through the nucleus reuniens and innervate the CRF neurons in the 
PVN may have been disconnected by this lesion. Since no inhibition of 
stress-induced renin secretion occurred in these rats, the data suggest 
that the fibers, and possibly cells, which mediate the effect of stress 
on renin secretion are different from the fibers and cells which mediate 
stress-induced corticosterone secretion. 
The nature of the PVN neurons which mediate the effect of stress 
on renin secretion is not known. It is clear, both from the present 
results and from studies by Porter (1988), that cells in the PVN play an 
important role in the regulation of renin secretion. Electrolytic lesions 
in the PVN prevent the increase in plasma renin activity after injection 
of the serotonin releasing drug p-chloroamphetamine (Gotoh et al., 1987). 
Furthermore, these lesions also prevent the increase in plasma renin 
activity that follows immobilization stress, although a reduction in 
plasma renin substrate (angiotensinogen) levels could account for this 
effect (Gotoh et al., 1987). It is important to note that, in the present 
study, a saturating concentration of exogenous renin substrate was added 
in the plasma renin concentration assay to control for possible variation 
of renin substrate in the plasma samples from the experimental rats. In 
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contrast, the plasma renin activity assay was a measure of the production 
of angiotensin I from endogenous renin, combined with endogenous renin 
substrate. Since plasma renin activity and concentration were equally 
affected by the lesions, the changes were clearly due to changes in renin, 
not renin substrate concentration in plasma. 
D. Injection of 6-0HDA into the PVN 
The main conclusion of the 6-0HDA experiment is that catecholaminer-
gic nerve terminals in the PVN mediate the effect of stress on both renin 
and corticosterone secretion. This conclusion is based on the observation 
that injection of 6-0HDA into the PVN inhibited the stress-induced 
increase in renin and corticosterone secretion. 6-0HDA is a neurotoxin 
that is taken up by the catecholaminergic nerve endings and produces 
degeneration of the nerve terminals (Breese and Traylor, 1970; Uretsky and 
Iversen, 1970). 6-0HDA is considered to be selective for catecholaminer-
gic neurons. Uretsky and Iversen (1970) reported that doses of 6-0HDA 
that decreased brain norepinephrine and dopamine levels did not affect 
brain serotonin or GABA. Shor-Posner et al. (1986) have reported that 
injection of 6-0HDA into the PVN, in the same dose as in my experiment, 
produced a 75% reduction in norepinephrine, 56% reduction of epinephrine 
and 47% reduction in dopamine concentration in the PVN. The catechol-
amines were determined by HPLC and electrochemical detection. Histochemi-
cal analysis also revealed a significant decrease in catecholamine 
fluorescence in the PVN. This study suggests that 6-0HDA can cause a 
degeneration of noradrenergic, adrenergic and dopaminergic elements in the 
PVN. Further support was provided by Fety et al. (1984), who injected 6-
0HDA into the fourth ventricle of rats to study the biochemical reponses 
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of the adrenergic (Cl, C2) cell groups versus the noradrenergic (Al, A2 
and A6) cell groups. Their results indicated that the adrenergic cell 
groups are sensitive to the neurotoxic effects of 6-0HDA since they 
exhibited changes in tyrosine hydroxylase and dopamine-&-hydroxylase in 
a similar manner to the noradrenergic cell groups. 
In the 6-0HDA experiment of this dissertation, norepinephrine 
depletion was verified immunocytochemically by using an antibody for 
dopamine-&-hydroxylase. No attempt was made to differentiate between loss 
of norepinephrine-, dopamine- or epinephrine-containing nerve terminals. 
Consequently, these results cannot indicate which catecholamine mediates 
the effects of stress on renin or corticosterone secretion. 
The suggestion that catecholaminergic nerve terminals in the PVN 
mediate stress-induced corticosterone secretion is supported by studies 
involving the ventral noradrenergic bundle (VNAB), which conveys most of 
the noradrenergic (Moore and Bloom, 1979; Palkovits, 1981; Swanson and 
Sawchenko, 1980) and adrenergic (Ungerstedt, 1971) afferents to the PVN. 
Injections of 6-0HDA into the VNAB inhibited the ACTH stress response 
(Szafarczyk et al. , 1985), prevented the increase in corticosterone 
secretion following photic, acoustic and sciatic nerve stimulation 
(Feldman et al., 1988), and significantly reduced CRF levels in hypophys-
ial portal blood (Guillaume et al., 1987). In addition, Feldman et al. 
(1986) demonstrated that 6-0HDA injections into the PVN significantly 
inhibit the adrenal response to photic, acoustic and sciatic nerve 
stimulation. Together, these results suggest a role for catecholaminergic 
afferents to the PVN in the activation of adrenocortical responses to 
stress. 
134 
The dorsal noradrenergic bundle (DNAB) may play a role as a 
mediator of stress-induced renin secretion. Some afferent fibers from 
the locus coeruleus travel to the PVN in the DNAB (Kobayashi et al., 1975; 
Loizou, 1969). Lightman et al. (1984) demonstrated that injections of 6-
0HDA into the DNAB markedly attenuate the increase in plasma renin 
activity in response to hemorrhage, while injections of 6-0HDA into the 
VNAB had no effect. This study, in combination with my results, suggests 
that catecholaminergic afferents to the PVN mediate the renin response to 
stress. 
E. Injection of Sotalol into the PVN 
Since the data suggest that catecholaminergic nerve terminals in 
the PVN mediate the stress-induced increase in renin and corticosterone 
secretion, the next question to address was whether or not E-adrenergic 
receptors mediate this effect. Previous studies demonstrated that the &-
adrenoceptor antagonist propranolol (1 mg/kg, i.p.) significantly 
attenuated the stress-induced increase in plasma renin activity (Van de 
Kar et al., 1985). Since propranolol is known to cross the blood-brain 
barrier (Garvey and Ram, 1975; Lemmer et al., 1985), and the PVN contains 
a high concentration of~ receptors (Wanaka et al., 1989), it is possible 
that a E-receptor, located in the PVN, could be involved in mediating the 
effect of stress on renin and corticosterone secretion. In the present 
experiment, sotalol was selected instead of propranolol because it is 
devoid of local anesthetic activity and is both a &1 and E2 antagonist 
(Fitzgerald, 1984). Injection of sotalol into the PVN prevented the 
stress-induced increase in corticosterone secretion but did not prevent 
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the stress-induced increase in renin secretion. This suggests that a &-
adrenergic receptor in the PVN plays a role in the corticosterone response 
to stress. However, many B-adrenoceptor antagonists also bind to 
serotonin receptors in the brain (Conway et al., 1978). Since only one 
dose of sotalol was administered, it is possible that this dose (15 nmol) 
could affect serotonergic as well as B-adrenergic receptors. Other 
investigators have injected much higher doses of sotalol and propranolol 
in the brain. Injections of sotalol (400 nmol) or propranolol (120 nmol) 
into the perif ornical region of the anterior hypothalamus did not prevent 
the feeding response induced by either epinephrine (20 nmol) or norepi-
nephrine (20 nmol). This feeding response was prevented by injections of 
the a-adrenoceptor antagonists phentolamine (30 or 60 nmol), tolazoline 
(100 nmol) or phenoxybenzamine (15 nmol) in the same brain region 
(Leibowitz, 1975). Injection of propranolol (116 nmol) or timolol (95 
nmol) into the cerebral ventricles prevented the effect of air stress on 
renal sympathetic nerve activity in spontaneously hypertensive rats. In 
addition, icv injection of propranolol (4 or 25 nmol) produced an 
inhibition of epinephrine-stimulated ACTH release (Szafarczyk et al., 
1987). In my study, the fact that sotalol inhibited the stress-induced 
increase in corticosterone secretion but not the stress-induced increase 
in renin secretion argues for a relative selectivity in receptor binding. 
Other investigators have provided evidence for the role of &-
receptors in the regulation of corticosterone secretion. Szafarczyk et 
al. (1987) demonstrated a stimulatory role for epinephrine and norepineph-
rine on corticosterone release. Injection (icv) of epinephrine or 
norepinehrine induced ACTH release comparable to that occuring under 
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(ether) stress conditions. Epinephrine was more efficacious than 
norepinephrine on an equimolar basis. The stimulating effect of 
norepinephrine was reversed by icv pretreatment with prazosin, an a 1 
antagonist, whereas the effect of epinephrine was inhibited by either 
prazosin or propranolol. These results suggest that norepinephrine 
stimulates ACTH release via a 1 receptors, whereas epinephrine acts via both 
a 1- and &-adrenoceptors. In vitro studies support the role of &-adrenergic 
receptors in CRF release. Norepinephrine stimulated the release of 
immunoreactive CRF from cultured neonatal rat hypothalamic cells. This 
effect was blocked by propranolol but not by prazosin. In addition, the 
E.-adrenoceptor agonist isoproterenol significantly increased CRF while the 
a-adrenoceptor agonist phenylephrine was ineffective, except at high 
concentrations (Widmaier et al., 1989). Together, these data strongly 
suggest a stimulatory role for &-receptors in the regulation of cor-
ticosterone secretion. 
To speculate as to which neurotransmitter could be involved in 
mediating the effect of stress on corticosterone secretion, several 
studies should be considered. Leibowitz et al. (1986) demonstrated that 
norepinephrine injections into the PVN dose-dependently increased serum 
corticosterone levels, while dopamine had no effect. Epinephrine in the 
PVN was even more efficacious than norepinephrine in increasing serum 
corticosterone levels. Further, a study by Spinedi et al. (1988) 
demonstrated that central inhibition of phenylethanolamine-N-methyltrans-
ferase (PNMT), producing a selective decrease in hypothalamic epinephrine 
levels, significantly decreased the plasma ACTH response to ether stress, 
and at later times also caused a selective decrease in CRF content. These 
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results support a stimulatory role of central epinephrine-containing 
neurons in CRF release. Sawchenko et al. (1987) estimated that at least 
40% of the retrogradely- labeled catecholaminergic cell groups that project 
to the PVN could be adrenergic (PNMT-immunoreactive). These results 
suggest that stress-induced increases in corticosterone levels could be 
mediated via adrenergic nerve terminals activating B-receptors in the PVN. 
Stress-induced increases in plasma renin activity and concentration 
are mediated by a different receptor. It is possible that an a-adrenergic 
receptor could mediate the stress-induced increase in renin secretion. 
However, pharmacological studies suggest that activation of brain a 2-
adrenoceptors lowers renin secretion by inhibiting sympathetic outflow to 
the kidneys. Injection of clonidine (icv) prevented the air jet stress-
induced increase in renal sympathetic nerve activity in spontaneously 
hypertensive rats. This effect was reversed by icv injection of the a 2-
adrenergic antagonists yohimbine and rauwolscine (Koepke and DiBona, 
1986). !CV injection of clonidine lowered plasma renin activity at a dose 
which is ineffective when given intravenously (Reid et al., 1975). Blair 
et al. (1977) demonstrated that administration of L-DOPA to dogs 
pretreated with the peripheral decarboxylase inhibitor carbidopa results 
in a drop in blood pressure and an inhibition of renin secretion. Since 
this treatment increases brain catecholamine content, the results suggest 
that catecholamines formed from L-DOPA can act within the central nervous 
system to cause a decrease in renin secretion. In this study the decrease 
in plasma renin activity was dependent upon the presence of the renal 
nerves. These studies suggest that central a 2-adrenoceptors are involved 
in decreasing renin secretion. However, it is possible that central a 1-
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adrenoceptors could mediate the stress-induced increase in renin 
secretion. Ganong et al. (1982) suggested that the activation of central 
a 1 receptors increases renin secretion in anesthetized dogs. However, 
these data are not very convincing since they only reported renin values 
following icv injection of the a 1-agonists methoxamine and phenylephrine, 
without the appropriate vehicle controls. 
The PVN has been shown to project to those segments of the thoracic 
cord containing sympathetic preganglioninc neurons innervating the kidney 
(Swanson and Mc Kellar, 1979). Other studies have suggested that the 
sympathetic nervous system mediates the stress response from the brain to 
the kidney (Golin et al., 1988). However, in our laboratory, (see STRESS: 
Effect of Peripheral Sympathectomy) sympathectomized-adrenal enucleated 
rats showed no inhibition of the stress-induced increase in plasma renin 
activity/concentration or plasma corticosterone levels (Richardson Morton 
et al., 1988). This suggests that the sympathetic nervous system and 
adrenal catecholamines are not the only mediators of the stress-induced 
increase in renin secretion. An alternate theory is that cell bodies in 
the PVN are stimulated to secrete a renin-releasing factor to the 
bloodstream to promote renin release from the kidneys (Van de Kar et al., 
1987). 
If a and~ receptors in the PVN do not mediate stress-induced renin 
secretion, another possibility is that a neuropeptide, coreleased at the 
catecholaminergic nerve terminals in the PVN, mediates stress-induced 
renin secretion. A likely candidate is neuropeptide Y, which is 
coexpressed in noradrenergic and adrenergic brain stem cell groups and is 
present in noradrenergic and adrenergic nerve terminals in the PVN 
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(Sawchenko et al., 1985). Intraventricular injection of NPY has been 
shown to increase plasma ACTH and corticosterone secretion (Harfstrand et 
al., 1987) and plasma angiotensin II levels (Harfstrand et al., 1986). 
However, Fuxe et al. (1983) reported that intracisternal injection of NPY 
causes hypotension, which could also increase renin secretion by 
activation of the intra-renal stretch receptor (Fahri et al., 1982). 
Yet another neuropeptide of interest is galanin, due to its 
preferential coexistance with noradrenergic cell groups that project to 
the PVN. Combined immunohistochemical-retrograde transport studies have 
demonstrated galanin-immunoreactivity coexisting with dopamine-&-
hydroxylase immunoreactivity in the Al and A6 cell groups, with no 
evidence for galanin coexistence in adrenergic (PNMT-immunoreactive) 
neurons that project to the PVN. Galanin inputs were confined to the 
anterior, periventricular, dorsal and ventral subdivisions of the 
parvocellular PVN, with only a sparse projection to the oxytocinergic 
neurons of the magnocellular division of the PVN (Levin et al, 1987). 
F. Hypothetical Organization of Brain Pathways Mediating 
Stress-Induced Renin and Corticosterone Secretion 
The neural pathways mediating stress-induced renin and cort-
icosterone secretion are likely to be complex and multi-synaptic, due to 
the many inputs which must be integrated. First, there is a sensory 
component that arises during behavioral conditioning. When the rat 
receives the foot shock as part of the conditioned fear paradigm, the 
sensory message is transmitted from the nerve fibers in the skin to the 
spinal cord, where it travels in the lateral spinothalamic tract to the 
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posteroventral nuclei of the thalamus. The spinothalamic fibers are 
accompanied by fibers that terminate in the reticular formation (spino-
reticular) and the periaqueductal gray and tectum (spinotectal). The 
periaqueductal grey has been shown to play a role in flight or defensive 
behavior (de Molina and Hunsperger, 1962). 
The pain input route most likely continues from the midbrain 
reticular formation, through the thalamus, to reach the septum and 
hippocampus. The septo-hippocampal system plays a major role in pain 
reception. The hippocampus emits a theta wave (4-9 cps rhythm) as a 
response to a painful stimulus in the rat, and in the emotional states of 
disappointment and frustration in humans. Lesions in the medial nuclei 
of the septum and the thalamic nucleus centrum medianum abolish the theta 
wave emitted by the hippocampus in response to a painful stimulus (Gray, 
1971). 
Damage to the hippocampus has been shown to facilitate acquisition 
of shuttle box avoidance (Green et al., 1967; Van Hoesen et al., 1972) 
possibly due to a deficit in a behavioral inhibitory system (Douglas, 
1967; Gray, 1982). These studies, and others (Squire and Zola-Morgan, 
1983), suggest a critical role of the hippocampal formation in learning 
and memory. The hippocampal formation and septa! region share extensive 
bidirectional connections. The lateral, medial and posterior divisions 
of the septa! regions are associated with the hippocampal formation while 
the ventral division (bed nuclei) is primarily related to the amygdala 
(Swanson et al., 1987). The subicular complex and the entorhinal area of 
the hippocampus receive an extensive sensory input from the cortex, 
including olfactory, visual, auditory and somatosensory. Additional 
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sensory information is relayed through two routes, one via the thalamus, 
extrahippocampal cortex and amygdala and the other via ascending pathways 
from the brainstem and basal forebrain. The hippocampus also receives 
considerable serotonergic input from the raphe nuclei (Azmitia, 1978; 
Lorens and Guldberg, 1974; Steinbusch, 1981). Immunoreactive-CRF neurons 
have been demonstrated in the hippocampus (Swanson, 1983). However, the 
axonal projections of these cells are relatively short, suggesting that 
they might function as interneurons (Kohler, 1986). 
The hippocampus has many interconnections to another limbic 
structure, the amygdala (Krettek and Price, 1978). The amygdaloid complex 
has been shown to be involved in the regulation of fear-motivated behavior 
(Blanchard and Blanchard, 1972; Spevack et al., 1975). The amygdala 
appears to play a role in the stress response via the pituitary-adrenal 
cortical axis . The central nucleus of the amygdala, in particular, 
contains large numbers of CRF-containing cell bodies and terminals 
(Swanson et al., 1983; Moga and Gray, 1985). Both the central and medial 
amygdaloid nuclei project to the thalamic nucleus reuniens (Aggleton and 
Mishkin, 1984). This helps to explain why lesions in the nucleus reuniens 
prevented the effect of stress on corticosterone secretion. 
Most amygdaloid nuclei project to the bed nucleus of the stria 
terminalis (BNST) and the hypothalamus. Since the hypothalamus also 
receives a substantial projection from the BNST, there exists a di-
synaptic route for the amygdala to modulate hypothalamic function (Krettek 
and Price, 1978). The BNST also receives fibers from the dorsal and 
median raphe nucleus (Azmitia and Segal, 1978), as well as a massive 
projection from the hippocampus (Swanson and Cowan, 1977). To summarize, 
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the incoming sensory information and "learning"/associative processes that 
accompany the conditioned fear paradigm are likely conveyed to the PVN via 
limbic regions of the telencephalon since direct neocortical projections 
to the hypothalamus cannot be demonstrated (Swanson et al., 1987). The 
hippocampus, amygdala and ventral septal region project heavily to the 
BNST, which in turn projects to the CRF regions of the PVN. The question 
that remains is: how does this input to the PVN become integrated with the 
direct nordrenergic (A2) and adrenergic (Cl-C3) input via the VNAB (brain 
stem to the CRF neurons in the PVN)? 
Swanson et al. (1983) suggested that the nucleus of the solitary 
tract, which receives direct vagal and glossopharyngeal afferents 
(Beckstead and Norgren, 1979) could serve as a major relay point of 
visceral sensory information to CRF cell bodies in the basal forebrain. 
Likewise the parabrachial nucleus, which receives a large input from the 
NTS (Norgren, 1978), and the locus coeruleus also project to many of the 
sites that contain CRF-immunoreactive cell bodies, including the 
parvocellular PVN, the bed nucleus of the stria terminalis and the central 
nucleus of the amygdala. As mentioned above, these nuclei may also be 
involved in the relay of visceral sensory information to CRF cell bodies 
(Swanson et al., 1983). This hypothetical pathway could provide a direct 
stimulus for corticosterone secretion. 
Another possibility is that the noradrenergic input to the PVN is 
serving as a neuromodulator to "set a bias" to amplify or buffer incoming 
stimuli to the cells. Even though norepinephrine might have little effect 
on the resting excitability of the CRF neurons, it could have profound 
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effects on the amount of CRF released following an action potential 
(Nicoll, 1982). For example, pretreatment with norepinephrine (5 µ.M) 
before iontophoretically-applied glutamate (50 nA) in a pyramidal 
(hippocampal) cell has been shown to evoke a higher frequency and longer 
duration train of action potentials than following glutamate alone 
(Madison and Nicoll, 1986). 
Wallace et al. (1989) demonstrated that the amygdala innervates the 
locus coeruleus (A6) and NTS (A2) noradrenergic cells, and the C2 
adrenergic cells. Most of the rostral A6 and A2 neurons had amygdaloid 
terminal contacts. This pathway could be involved in integrating the 
sensory/associative processes with the stimulatory catecholaminergic 
afferents to the PVN. 
The possibility exists that serotonergic neurons play a role in 
transmitting the stress stimulus. The dorsal raphe nucleus (B7) is one 
of the nine 5-HT cell groups originally described by Dahlstrom and Fuxe 
(1965), which innervates the forebrain. Studies from our laboratory have 
shown that electrolytic lesions in the dorsal raphe nucleus prevent the 
stress-induced increase in plasma renin activity using a three-minute CER 
(Van de Kar et al., 1984). This experiment was repeated, extending the 
CER to ten minutes so that corticosterone levels could be evaluated. 
Confirming the previous results, we found that electrolytic lesions in the 
dorsal raphe nucleus prevented the stress - induced increase in plasma renin 
activity and concentration and corticosterone levels (Richardson Morton 
et al., 1986). There could be a connection between the fact that both 
dorsal raphe lesions and PVN lesions prevent the stress-induced increase 
in plasma renin activity, plasma renin concentration and corticosterone 
levels. 
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Sawchenko et al. (1983) have demonstrated that serotonergic 
neurons in the midbrain (especially the dorsal raphe) innervate the PVN. 
Although the serotonergic fiber density in the PVN is low compared with 
immediately surrounding areas, there is a distinct projection to the 
medial parts of the parvocellular division. Liposits et al. (1987) have 
demonstrated by electron microscopic methods that serotonergic nerve 
terminals innervate CRF-immunoreactive parvocellular cells in the PVN. 
Injections (i.p.) of the 5-HT2 antagonist, LY53857, did not prevent 
the stress-induced increase in renin or corticosterone secretion 
(Richardson Morton et al., 1986). However, injection of the 5-HT1A 
agonists buspirone and ipsapirone significantly attenuated the stress-
induced increase in plasma renin activity, plasma renin concentration and 
corticosterone levels (Urban et al., 1986; Van de Kar et al., 1985; Lorens 
et al. , 1989). Both buspirone and ipsapirone inhibit the firing of 
serotonergic neurons in the dorsal raphe (Basse-Tomusk, 1986; VanderMaelen 
et al., 1986). Thus, serotonergic neurons in the dorsal raphe nucleus 
could be involved in stress-induced renin and corticosterone secretion. 
There are fiber projections from the locus coeruleus to the dorsal raphe 
nucleus (Cowan and Park, 1986), with direct noradrenergic nerve terminal 
innervation of serotonin nerve cells in the dorsal raphe (Baraban and 
Aghajanian, 1981), and projections from the dorsal raphe to the locus 
coeruleus (Conrad et al., 1974). These interconnections could provide a 
relay for the noradrenergic bundles to influence hypothalamic neuroen-
docrine responses. 
Another possibility is that the dorsal raphe serotonergic neurons, 
which also project to the hippocampus (Swanson et al., 1987), provide a 
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tonic inhibition of the "behavioral inhibition" system of the hippocampus. 
In this case, administration of 5-HT1A anxiolytic agents or electrolytic 
lesions in the dorsal raphe nucleus would decrease the input to the septo-
hippocampal system, thus reducing the activity of the septo-hippocampal 
behavioral system, ultimately decreasing the behavioral and possibly 
neuroendocrine stress response (Kuhar, 1986). 
Clearly, the neural pathways mediating stress-induced renin and 
corticosterone secretion are complex and multi-synaptic. From this 
dissertation, it can be concluded that stress-induced corticosterone 
secretion appears to be mediated by Preceptors in the PVN, while stress-
induced renin secretion is mediated by a receptor that is not P-adrener-
gic. Stress- induced renin secretion may be mediated by a different 
catecholamine receptor, a neuropeptide or other substance(s) colocalized 
in catecholaminergic nerve terminals. 
The following figure is a schematic diagram of the hypothetical 
brain pathways mediating stress-induced renin and corticosterone 
secretion. 
FIGURE 24 
Hypothetical Brain Pathways Mediating 
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